Schmallenberg Virus

Overview and Taxonomy of Schmallenberg Virus

Taxonomic Position and Genomic Organization

Schmallenberg virus (SBV) is a newly emerged, arthropod-borne pathogen that was first identified in November 2011 from dairy cattle exhibiting pyrexia, decreased milk yield, and diarrhoea on a farm near the German town of Schmallenberg at the Dutch-German border [1, 11, 18]. The virus was discovered through metagenomic analysis after targeted diagnostic investigations failed to identify a causal agent among classical endemic and emerging viruses [11, 24]. Since its initial detection, SBV has been definitively classified within the genus Orthobunyavirus, family Peribunyaviridae (formerly Bunyaviridae), and belongs to the Simbu serogroup, a taxon that encompasses a number of veterinary and human pathogens including Akabane virus, Aino virus, Shamonda virus, and Oropouche virus [1, 8, 18, 25]. This taxonomic placement is critical because it informs our understanding of the virus’s biological behavior: orthobunyaviruses are characterized by a tripartite, negative-sense, single-stranded RNA genome that is encapsidated by the viral nucleoprotein (N) and packaged within a lipid envelope derived from the host cell membrane [18, 25]. The three genomic segments are designated large (L), medium (M), and small (S). The L segment encodes the RNA-dependent RNA polymerase (RdRp), which is essential for viral replication and transcription. The M segment encodes a single polyprotein that is co-translationally cleaved into the two surface glycoproteins, Gn and Gc, as well as a non-structural protein known as NSm [7, 18, 25]. The S segment, in contrast, encodes the nucleoprotein (N) and, via an overlapping reading frame in an ambisense strategy common to orthobunyaviruses, a second non-structural protein designated NSs [7, 18]. The Gc protein, which functions as a class II fusion protein, is particularly noteworthy because it mediates the critical step of membrane fusion during viral entry and serves as the primary target for virus-neutralizing antibodies [5, 10, 21].

The genetic organization of SBV is remarkably similar to that of other Simbu serogroup viruses, such as Akabane virus, with which it shares a high degree of sequence homology [8, 18, 21]. This homology has practical implications for serological diagnostics: it can cause cross-reactivity in antibody detection assays when attempting to differentiate SBV from related orthobunyaviruses, as has been demonstrated in studies where ELISA-positive samples from the Middle East were subsequently shown by virus neutralization tests to be caused by Aino virus rather than SBV itself [28]. From an evolutionary perspective, the sequence of the M segment, and particularly the glycoprotein Gc, has been used extensively in phylogenetic analyses to trace the virus’s emergence and spread. Remarkably, the M segment sequences of SBV strains circulating in the blood of viremic adult cattle and sheep have proven to be extraordinarily stable across Europe over nearly a decade, with nucleotide similarities as high as 99.4% to 100% between viruses sampled in different years and different countries [12, 14]. This genomic stability among circulating strains stands in stark contrast to the high genetic variability observed in SBV variants isolated from malformed fetuses, where point mutations, insertions, and large in-frame deletions within the N-terminal region of the Gc protein have been documented [6, 7, 14]. This dichotomy is a defining feature of SBV biology and is central to understanding its transmission dynamics and evolutionary trajectory.

Evolutionary Relationships and the Simbu Serogroup

The Simbu serogroup of orthobunyaviruses comprises at least 25 distinct virus species, many of which are transmitted by Culicoides biting midges and are known to cause reproductive disease in ruminants [18, 25]. SBV is phylogenetically most closely related to Akabane virus, Shamonda virus, and Aino virus, forming a clade of viruses that share a similar ecological niche and pathogenic profile [8, 18, 28]. Akabane virus, which was first described in Japan in 1959, is the archetype of this group and is endemic in tropical and subtropical regions of Africa, the Middle East, Asia, and Australia [18]. The emergence of SBV in temperate Europe, however, demonstrated that these viruses are not confined to warm climates; indeed, SBV rapidly achieved a pan-European distribution within two years of its initial detection, infecting domestic and wild ruminants in countries from Scandinavia to the Mediterranean [11, 16, 22, 23]. The virus was able to spread to high altitudes, up to 1500 meters, in mountainous regions of France and Spain, a capacity that exceeded that of bluetongue virus (BTV), another Culicoides-borne pathogen, which had previously been restricted to lower elevations [22]. This expansive ecological range underscores the remarkable adaptability of SBV and highlights the potential for its further geographic expansion.

A critical area of research has been the investigation of genetic variants that arise within infected fetuses. Sequence analysis of SBV from viremic animals reveals very high genome stability, whereas variants from malformed fetuses display a remarkable degree of sequence variation, particularly in the M segment’s “hot-spot” region encoding the N-terminal domain of Gc [6, 14, 15]. This domain co-localizes with the main immunogenic region of the protein, and mutations within this area, including single amino acid substitutions, small insertions, and even deletions of up to 612 nucleotides, have been shown to confer a phenotype of immune evasion from neutralizing antibodies [14]. The large-deletion variant designated SBV_D281/12, which was isolated from the brain of a malformed ovine fetus, harbors a large genomic deletion in the antigenic domain of the M segment along with multiple point mutations in all three genome segments [6, 7]. Remarkably, this variant showed a marked replication deficiency in Culicoides sonorensis cells (KC cells) and failed to replicate at all in laboratory-reared C. sonorensis midges after oral feeding [6, 7]. This loss of fitness in the insect host, mediated specifically by a single point mutation (S to N at position 111) in the nucleoprotein encoded by the S segment, has led to the hypothesis that such “dead-end” variants arise in the unique immunological environment of the developing fetus but are subsequently excluded from the natural insect-mammalian transmission cycle because they cannot infect or replicate in the vector [6, 7]. These findings have profound implications for molecular epidemiology: such mutant strains should not be included in attempts to trace the spatial-temporal evolution of orthobunyaviruses during outbreak investigations, as they do not represent the circulating virus population [14].

Molecular Virology and Host-Cell Interactions

The viral life cycle of SBV begins with attachment to the host cell surface, a process that is mediated by the Gn and Gc glycoproteins. Using an unbiased genome-wide CRISPR-Cas9 forward genetic screen, Thamamongood et al. identified the host factor PAPST1 (3′-phosphoadenosine 5′-phosphosulfate transporter 1), encoded by the SLC35B2 gene, as an essential entry factor for SBV [13]. PAPST1 is a sulfotransferase required for the synthesis of heparan sulfate proteoglycans (HSPGs) on the cell surface. Knockout of SLC35B2 dramatically reduced SBV attachment and entry, and treatment of cells with heparinase, an enzyme that cleaves heparan sulfate, similarly diminished infection [13]. Importantly, this dependency on heparan sulfate was also observed for two other bunyaviruses, La Crosse virus (genus Orthobunyavirus) and Rift Valley fever virus (genus Phlebovirus), suggesting that HSPGs serve as a universal attachment factor for many members of the order Bunyavirales [13]. These findings align with the historical understanding that bunyaviruses often use cellular glycosaminoglycans as initial docking sites, a strategy that is particularly important for viruses that must infect a wide range of cell types in both mammalian and insect hosts.

Following attachment, the virus enters the cell via receptor-mediated endocytosis, and the Gc protein mediates the low-pH-dependent fusion of the viral envelope with the endosomal membrane [5, 10]. The Gc protein is a class II fusion protein, and its fusion activity is dependent on the presence of the Gn protein, which is thought to stabilize Gc in its prefusion conformation [5]. Recent research using overlapping peptides spanning the entire Gn and Gc amino acid sequences has identified five peptides, all located in the C-terminal domain of Gc, that inhibit SBV infection in vitro with 50% inhibition at concentrations of approximately 100 µM [5]. These findings identify new putative domains within Gc that are involved in the penetration process and offer potential targets for the development of antiviral therapeutics. In a separate study, scorpion-derived host defense peptides (pantinin-1 and pantinin-2) were shown to exhibit potent virucidal activity against SBV, with IC50 values of approximately 10 µM and favorable selectivity indices across different cell lines, underscoring the broader potential of venom-derived peptides as antiviral agents [4].

Once the virus enters the cytoplasm and uncoats, the negative-sense genomic RNA is transcribed by the viral RdRp into mRNAs for protein synthesis. The replication cycle also involves the manipulation of host cellular pathways. Longobardi et al. demonstrated that SBV infection of baby hamster kidney (BHK-21) cells induces autophagy at 48 hours post-infection, as evidenced by the upregulation of LC3-II and changes in the PI3K/Akt signaling pathway [3]. Interestingly, the same study revealed that the Wnt/β-catenin pathway, a critical regulator of cell proliferation and differentiation, is significantly downregulated during infection, with β-catenin expression almost disappearing regardless of the multiplicity of infection [3]. The use of late-stage autophagy inhibitors, such as bafilomycin and chloroquine, significantly reduced SBV replication, suggesting that autophagic flux is required for efficient virus production [3]. These findings point to a central role for the late stages of autophagy in the SBV replication cycle and open new avenues for antiviral intervention. Additionally, the non-structural proteins NSs and NSm have been studied for their roles in infection. Using reverse genetics, Wernike et al. generated recombinant SBV variants lacking NSs, NSm, or both proteins and fed them to laboratory-reared Culicoides sonorensis midges [7]. Remarkably, the deletion of these non-structural proteins had no obvious effect on the oral susceptibility of the midges to virus infection: 1.55–2.78% of midges fed with the deletion mutants displayed viral loads higher than those in the day-0 control groups, comparable to the 2% infection rate observed for the wild-type strain [7]. This finding indicates that, at least in the insect host, NSs and NSm are not essential for the establishment of infection or replication, a result that contrasts with the roles of these proteins in mammalian hosts where NSs is known to function as an interferon antagonist.

From an immunological standpoint, the innate immune response to SBV is partly mediated by Mx proteins, which are interferon-inducible GTPases that exhibit antiviral activity against a wide range of RNA viruses. Bayrou et al. investigated the anti-SBV activity of Mx1 proteins from bovine, canine, equine, and porcine species and concluded that Mx1 has a strong, dose-dependent antiviral effect against SBV in all four domestic species [9]. This work underscores the importance of the type I/type III interferon system in controlling SBV infection and suggests that Mx1 polymorphisms could contribute to differential susceptibility among breeds or individuals. At the level of adaptive immunity, the N-terminal domain of the Gc protein, specifically the Gc head and head-stalk domains, has been identified as the major target of neutralizing antibodies [10, 21]. Subunit vaccines based on this domain, delivered via recombinant viral vectors such as modified vaccinia virus Ankara (MVA), have been shown to confer full protection against SBV challenge in cattle while enabling differentiation of infected from vaccinated animals (DIVA) due to the absence of antibodies against the N protein [10, 21, 27]. Furthermore, immunization with a small, highly conserved fragment of the nucleoprotein (the C4 fragment, Met1-Ala58) protected IFNAR-/- mice against virulent SBV challenge, and this fragment shares approximately 87.1% sequence homology with corresponding regions in other Simbu serogroup viruses, suggesting its potential as a cross-protective vaccine antigen [8].

The taxonomic classification of SBV as an orthobunyavirus within the Simbu serogroup is not merely a matter of nomenclature; it dictates the virus’s vector associations, its pathogenic mechanisms, and its epidemiological behavior. Like other members of the serogroup, SBV is transmitted primarily by biting midges of the genus Culicoides (Diptera: Ceratopogonidae), and the virus has been detected in multiple vector species across Europe, including the Obsoletus complex (C. obsoletus, C. scoticus, C. dewulfi, C. chiopterus), the Pulicaris complex (C. punctatus, C. pulicaris, C. lupicaris), and even C. imicola in southern Europe [2, 19, 20]. The minimum infection rates (MIR) in vector populations vary substantially between years and locations. For example, in the German monitoring program from 2019–2023, the MIR of SBV in midge pools ranged from 3.75 in 2022 to 135.47 in 2023, reflecting the wave-like patterns of virus circulation that are characteristic of an enzootic system [2]. The ability of SBV to overwinter in the vector, or perhaps in persistently infected hosts, and to re-emerge when herd immunity wanes has led to the establishment of a predictable pattern of recirculation every 2–4 years in endemic regions of Central Europe [10, 12, 17, 26]. This cyclical re-emergence, combined with the expanding geographic range of the virus due to climate change and global trade, makes SBV a pathogen of enduring concern for veterinary public health authorities, including the World Organisation for Animal Health (WOAH), which has classified SBV as an emerging disease with significant economic implications for the ruminant livestock industry worldwide.

Molecular Pathogenesis of Schmallenberg Virus

The molecular pathogenesis of Schmallenberg virus (SBV) represents a paradigmatic study in host–virus coevolution, arboviral restriction, and teratogenic mechanisms. As a member of the genus Orthobunyavirus within the family Peribunyaviridae and the Simbu serogroup, SBV possesses a tripartite negative-sense single-stranded RNA genome comprising the large (L), medium (M), and small (S) segments [1, 18, 25]. The L segment encodes the viral RNA-dependent RNA polymerase (RdRp), the M segment encodes a polyprotein precursor that is post-translationally cleaved into the envelope glycoproteins Gn and Gc, as well as the non-structural protein NSm, and the S segment encodes the nucleocapsid protein N and, via an overlapping open reading frame, the non-structural protein NSs [1, 7, 18]. It is the unique interplay of these structural and non-structural components with host cellular machinery that dictates viral tropism, replication kinetics, immune evasion, and ultimately the capacity for transplacental transmission and fetal damage.

Viral Entry and Cellular Tropism: The Role of Heparan Sulfate and Glycoprotein Architecture

The initial step in SBV infection requires efficient attachment to and entry into permissive host cells. Genome-wide CRISPR-Cas9 forward screening has definitively identified the solute carrier family 35 member B2 gene (SLC35B2), encoding 3′-phosphoadenosine 5′-phosphosulfate transporter 1 (PAPST1), as an essential host entry factor for SBV [13]. PAPST1 is a Golgi-resident sulfotransferase critical for the biosynthesis of heparan sulfate proteoglycans (HSPGs). Knockout of SLC35B2 in permissive cell lines dramatically reduced SBV cell-surface attachment and entry, while reconstitution fully restored susceptibility [13]. Furthermore, enzymatic removal of heparan sulfate from the cell surface using heparinase significantly diminished SBV infection, confirming that HSPGs serve as critical attachment factors [13]. This dependency on heparan sulfate is not unique to SBV; it is shared by other bunyaviruses including La Crosse virus and Rift Valley fever virus, underscoring a common evolutionary adaptation for cell-surface glycosaminoglycan utilization among arthropod-borne members of the Bunyavirales [13].

The viral glycoproteins Gn and Gc, encoded by the M segment, mediate the subsequent steps of receptor binding and membrane fusion. Gc is a class II fusion protein, and its fusion activity is strictly dependent on the prior presence of Gn, which facilitates proper folding and transport of the glycoprotein complex to the virion surface [5]. The N-terminal domain of Gc, particularly the region encompassing amino acids 1–234 (termed “Gc Amino”), has been identified as a highly immunogenic domain that also contains the principal neutralizing epitopes [10, 21]. Detailed peptide scanning across the entire Gc and Gn sequences revealed that five overlapping peptides derived from the C-terminal region of Gc exhibited >50% inhibition of SBV infection in vitro, while none of the 20 Gn-derived peptides showed inhibitory activity [5]. This finding suggests that the C-terminal portion of Gc contains domains critical for post-attachment entry steps, possibly including fusion pore formation or intracellular trafficking of the viral ribonucleocapsid.

Autophagy, Wnt/β-Catenin Signaling, and the Intracellular Replication Niche

Once internalized, SBV must navigate the host cell’s innate antiviral defenses while co-opting cellular organelles and metabolic pathways to establish a productive replication cycle. Phenotypic analysis of SBV-infected baby hamster kidney (BHK-21) cells has revealed profound dysregulation of two major cellular signaling pathways: autophagy and the Wnt/β-catenin cascade [3]. Western blot analysis demonstrated that SBV infection induces autophagy at 48 hours post-infection, as evidenced by increased LC3-II levels. However, the virus simultaneously downregulates critical upstream regulators of autophagy, including PI3K, Akt, and the mechanistic target of rapamycin (mTOR). Notably, the expression of Beclin-1, a key initiator of autophagosome formation, showed differential sensitivity to the multiplicity of infection (MOI): differences were observed between MOI 0.05 and 0.5 but not between MOI 0.5 and 1.5, suggesting a threshold-dependent regulation [3].

The functional significance of autophagy for SBV replication was elegantly demonstrated using chemical modulators. Late-stage autophagy inhibitors, particularly bafilomycin A1 (which blocks autophagosome-lysosome fusion) and chloroquine (which alkalinizes the lysosomal pH), significantly reduced SBV infectivity and prevented virus-induced changes in cellular protein expression [3]. In contrast, early-stage autophagy inhibitors (e.g., 3-methyladenine) and autophagy inducers (e.g., rapamycin) had no effect on viral titers or cell viability [3]. This pattern indicates that while the early steps of autophagosome formation are dispensable for SBV replication, the late stages of autophagic flux (i.e., autophagosome maturation and lysosomal degradation) are actively required, likely providing membranes or a protected cytoplasmic niche for viral replication complex assembly.

Concurrently, SBV infection induced a dramatic downregulation of β-catenin, such that its expression almost disappeared regardless of the MOI used [3]. Given that β-catenin is the central transcriptional co-activator of the canonical Wnt signaling pathway, its degradation has far-reaching consequences for host gene expression, including the suppression of genes involved in cell proliferation, differentiation, and innate immunity. Silencing Akt and β-catenin expression via RNA interference resulted in a modest but reproducible increase in SBV Gc glycoprotein expression [3], suggesting that the virus-driven suppression of these pathways may represent a host attempt to restrict viral replication, which the virus overcomes through other compensatory mechanisms.

Interferon Antagonism and the Non-Structural Protein NSs

A defining feature of orthobunyavirus pathogenesis is the potent interferon (IFN) antagonism mediated by the NSs protein. SBV NSs, encoded by the S segment, is a multifunctional protein that suppresses host innate immune responses by inhibiting cellular transcription and by interfering with the type I/III interferon signaling axis [1, 7]. The biological relevance of NSs for viral fitness is underscored by studies using recombinant SBV deletion mutants. When laboratory-reared Culicoides sonorensis midges were fed blood meals containing wild-type SBV or mutants lacking NSs, NSm, or both, the absence of these non-structural proteins had no obvious effect on the oral susceptibility of the midges to infection: 2.78% of midges fed the NSs-deletion mutant, 1.92% fed the NSm-deletion mutant, and 1.55% fed the double-deletion mutant displayed viral loads above baseline, compared to 2% for wild-type [7]. Thus, while NSs is essential for counteracting the mammalian IFN response, it appears dispensable for infection of the insect vector, highlighting the host-specific nature of its function.

The host cell’s first line of antiviral defense also involves interferon-induced Mx GTPases. Bovine, canine, equine, and porcine Mx1 proteins have all been shown to exert strong, dose-dependent anti-SBV activity [9]. The mechanism likely involves recognition and sequestration of viral nucleocapsids or interference with viral polymerase function, although the precise molecular details for SBV-specific restriction remain to be fully elucidated. Given that Mx proteins are evolutionary sculpted by the “arms race” between host and pathogen, the ability of SBV to antagonize Mx function, or to evade detection by Mx orthologs, represents a critical determinant of host range and species susceptibility [9].

The M Segment “Hot Spot” and Immune Evasion in the Fetal Compartment

Perhaps the most striking molecular pathological feature of SBV is its capacity to generate highly diverse viral variants specifically within the environment of the developing fetus. Sequence analysis of SBV from malformed fetuses has consistently revealed a “hot-spot” region of extraordinary genetic variability within the N-terminal domain of the Gc protein, co-localizing precisely with the key immunogenic domain recognized by neutralizing antibodies [14, 18]. This hot spot accumulates point mutations, small insertions, and large in-frame deletions of up to 612 nucleotides. When recombinant Gc proteins carrying these fetal-derived mutations were tested against a panel of neutralizing monoclonal antibodies and domain-specific antisera, they universally failed to react, demonstrating that these alterations confer efficient immune evasion [14].

Remarkably, a natural isolate from a malformed fetus (strain D281/12) harbored a large genomic deletion in the M segment antigenic domain and multiple point mutations across all three genome segments. This variant could not be neutralized by SBV-specific polyclonal antisera or monoclonal antibodies in vitro [14]. However, this immune evasion came at a significant fitness cost: the D281/12 variant was severely attenuated in Culicoides sonorensis cells (KC cells) and completely failed to replicate in live C. sonorensis midges following oral feeding [6, 7]. The determinant of this replication deficit was mapped to the S segment, and specifically to a single point mutation at position 111 of the nucleoprotein (S→N) [6]. The S111N mutation is found exclusively in samples from malformed fetuses and never in the blood of viremic adult animals, confirming that these variants are “dead-end” products of fetal replication that cannot re-enter the natural insect–mammalian transmission cycle [6, 7, 14].

This phenomenon has profound implications for orthobunyavirus evolution and epidemiology. The fetal compartment provides a unique immunological milieu, one that is partially tolerogenic and lacks a fully developed adaptive immune system, which permits the outgrowth of variants that would be rapidly cleared in an immunocompetent adult. The resulting mutants, although immune-evasive, lose fitness for the insect vector and thus represent an evolutionary cul-de-sac. Importantly, such mutant strains should not be included in phylodynamic analyses aimed at tracing spatial-temporal viral spread, as they do not represent circulating, transmissible lineages [14].

Role of the Nucleoprotein and Segmental Reassortment Potential

The SBV nucleoprotein (N) is not merely a structural scaffold; it plays a central role in viral RNA encapsidation, replication, and transcription. The N protein has been demonstrated to be a potent immunological target. In DNA vaccination studies, constructs encoding full-length N (ubiquitinated or non-ubiquitinated) elicited high antibody titers, but only the non-ubiquitinated candidate provided statistically significant protection against virulent SBV challenge in IFNAR-/- mice [32]. Furthermore, a small fragment of the N-terminal domain of N (residues Met1–Ala58, termed “C4”) is highly conserved across the Simbu serogroup (approximately 87.1% homology with Akabane virus, Aino virus, and Oropouche virus) and, when used as a subunit vaccine, significantly reduces viremia and clinical signs in challenged mice [8]. The mechanism of protection appears to be cell-mediated, as evidenced by interferon-γ secretion from re-stimulated splenocytes in the absence of detectable neutralizing antibodies [8, 31].

The segmented nature of the SBV genome also confers the theoretical capacity for genetic reassortment. Although natural reassortment events between field strains of SBV have not been extensively documented, the co-circulation of multiple orthobunyaviruses (e.g., Akabane virus, Aino virus) in overlapping geographic regions raises the possibility of segment exchange, which could generate novel viruses with altered pathogenicity or host range [1, 18]. This potential, combined with the high mutation rate inherent to RNA-dependent RNA polymerases, makes SBV a virus with significant evolutionary plasticity.

Tissue Tropism, Transplacental Transmission, and Fetal Pathogenesis

The tropism of SBV for the developing fetal nervous system is the molecular basis of the arthrogryposis-hydranencephaly syndrome that defines the disease in newborn ruminants [1, 18, 25, 29]. Following infection of a pregnant, immunologically naïve dam during a critical window of gestation (typically between day 75 and 120 of gestation in cattle, and days 30–50 in sheep), the virus crosses the placenta and replicates in the fetal brain. The pathogenesis involves direct viral cytopathic effects, neuronal necrosis, gliosis, and mononuclear perivascular cuffing, leading to the development of hydranencephaly, porencephaly, cerebellar hypoplasia, and secondary neurogenic muscular atrophy (arthrogryposis) [1, 18]. The S segment mutations described above, particularly those in N that attenuate insect vector replication, do not impair replication in mammalian cells (e.g., BHK-21 cells), indicating that fetal brain tissue provides a permissive environment for these variants [6].

In adult ruminants, SBV infection is typically subclinical or causes only mild, transient disease characterized by fever, anorexia, diarrhea, and a decrease in milk production [1, 25, 29]. The molecular basis for this age- and pregnancy-dependent pathogenesis is multifactorial, involving the interplay of viral glycoprotein interactions with fetal cell receptors, the immature fetal immune system, and the unique metabolic environment of the developing brain. The World Organisation for Animal Health (WOAH) recognizes SBV as an important emerging pathogen for which surveillance and vaccine strategies must be tailored to the cyclical re-emergence patterns now established in Europe [1, 30].

Epidemiology and Global Spread of Schmallenberg Virus

The emergence of Schmallenberg virus (SBV) in late 2011 near the German town of Schmallenberg, at the border region with the Netherlands, marked the beginning of one of the most rapidly expanding epizootics of a novel vector-borne pathogen in modern veterinary history [1, 11, 18]. Within a remarkably short timeframe, SBV, an orthobunyavirus of the Simbu serogroup transmitted by Culicoides biting midges, achieved a pan-European distribution and subsequently extended its reach into Asia and Africa, establishing an enzootic status in several regions [1, 18, 33]. The epidemiological trajectory of SBV is characterized by an initial explosive epidemic wave, followed by a transition to cyclical re-emergence patterns driven by waning herd immunity and the continuous presence of competent vectors [12, 17, 45]. Understanding the intricate dynamics of SBV's global spread, its transmission ecology, and the factors governing its persistence is paramount for designing effective surveillance and control strategies, particularly in the face of climate change and intensified international animal trade [1, 30].

Initial Emergence and Explosive Pan-European Spread

The index cases of SBV were identified through metagenomic analysis of blood samples from dairy cattle exhibiting pyrexia, diarrhea, and a sharp drop in milk yield in North Rhine-Westphalia, Germany, and the Netherlands in the late summer and autumn of 2011 [11, 24, 25]. The virus was rapidly characterized as a novel orthobunyavirus within the Simbu serogroup, closely related to Akabane, Aino, and Shamonda viruses [18, 25]. The initial clinical signs, while economically significant, were relatively nonspecific. However, the true devastating impact of SBV became apparent in the winter of 2011/2012, when an unprecedented wave of abortions, stillbirths, and severe congenital malformations, predominantly arthrogryposis and hydranencephaly, was reported in newborn lambs, calves, and goat kids across continental Europe [1, 11, 18]. This temporal lag between the initial vector-borne transmission and the manifestation of teratogenic effects is a hallmark of SBV epidemiology, as infection of a naïve pregnant dam during a critical window of gestation leads to vertical transmission and fetal pathology, which is only observed at parturition months later [18, 29].

The speed of SBV's continental dissemination was extraordinary. By the end of 2012, the virus had been detected in virtually all countries of Western, Central, and Northern Europe, including Belgium, France, the United Kingdom, Denmark, Italy, Spain, Poland, and Slovenia [11, 20, 22, 43, 45, 46]. Retrospective analyses of Culicoides collections and serological samples revealed that SBV had been circulating in France as early as August 2011, months before the first congenital cases were recognized, highlighting the silent spread of the virus within vector populations [20]. The primary mechanism for this rapid long-distance dispersal was the wind-borne transport of infected Culicoides midges. Atmospheric dispersion modeling studies, particularly for the introduction of SBV into Ireland in October 2012, strongly support a single, successful long-range incursion event of infected midges from Southern England, facilitated by suitable meteorological conditions on August 10–11, 2012 [55]. This mechanism of aerial dispersal explains the seemingly simultaneous emergence of the virus in geographically disparate regions, outpacing the movement of infected livestock [55]. By the end of the initial epidemic (2011–2013), seroprevalence in domestic ruminants in many heavily affected areas had reached extraordinarily high levels, often exceeding 80–90%, indicating that the vast majority of the susceptible population had been exposed and had developed immunity [11, 56].

Establishment of Endemicity and Cyclical Re-Emergence

Following the initial massive epidemic, a critical epidemiological question was whether SBV would become endemic in Europe or fade out. Longitudinal serosurveillance studies across the continent have unequivocally demonstrated that SBV established an enzootic status, characterized by a distinct pattern of wave-like re-emergence occurring every 2 to 4 years [12, 17, 26, 45]. This cyclical pattern is primarily driven by the demographic turnover of the ruminant population. As immune animals are culled and replaced by naïve youngstock, the overall herd immunity gradually declines, eventually reaching a threshold that permits renewed large-scale virus circulation [17, 26, 56].

This phenomenon has been meticulously documented in several European countries. In Germany, where SBV was first detected, the virus re-emerged in 2014, 2016, and again in 2019, with a particularly extensive circulation event in 2023 [2, 12, 35]. A sentinel herd study in Germany demonstrated that within-herd seroprevalence declined from approximately 75% in 2011 to just 40% by 2015, before rising again to nearly 50% in 2016 and 2017 due to renewed virus circulation [26]. Crucially, this study showed that the decline in herd immunity was due to the introduction of seronegative young animals, not a loss of antibodies in previously infected individuals, as most cattle remained seropositive for at least six years post-infection [26]. Similarly, in Belgium, after a period of epidemiological silence, a significant resurgence of SBV was detected in the summer of 2016, with overall seroprevalence in sheep rising from 25% to 62% and between-herd prevalence increasing from 60% to 96% [51]. This resurgence was corroborated by the detection of SBV RNA in Culicoides obsoletus complex midges, confirming active transmission [51]. In Poland, a six-year serosurvey (2013–2018) revealed fluctuating annual seroprevalence, with peaks in 2014 and 2017, and continuous seroconversion in young animals, confirming endemic circulation with cyclical waves every 3–4 years [45]. The United Kingdom experienced a similar pattern, with major outbreaks in 2011/2012, a re-emergence in 2016/2017, and further circulation in 2021/2022, consistent with a cycle of approximately 3–6 years [29, 37, 49]. The 2016 re-emergence in Ireland was particularly well-documented, with seroprevalence in previously exposed dairy herds rising to 77.7%, demonstrating a new epidemic wave [54].

This cyclical pattern is now a predictable feature of SBV epidemiology in endemic regions. The World Organisation for Animal Health (WOAH) recognizes this dynamic, which necessitates continuous surveillance to anticipate periods of high risk for fetal malformations [1, 30]. The consequences of this cyclical immunity are significant: periods of low circulation lead to a large population of naïve, pregnant animals, setting the stage for future outbreaks of congenital disease when the virus inevitably re-emerges [17, 30].

Global Expansion: Beyond Europe into Asia and Africa

While the initial emergence and subsequent endemic cycling of SBV were centered in Europe, the virus has demonstrated a capacity for intercontinental spread, with detections reported in Asia and Africa. The Middle East represents a critical geographic bridge, and serological and molecular evidence has confirmed SBV circulation in several countries in this region. In Israel, genomic detection of SBV was reported in both Culicoides midges and affected ruminants between June 2018 and December 2019, marking the first confirmed circulation of the virus in the region and highlighting its potential to serve as an epidemiological bridge for spread into Asia [15]. In Turkey, the detection of SBV or closely related Simbu serogroup viruses has been suggested, and further serological work in Jordan identified antibodies against a Simbu serogroup virus, though cross-neutralization tests indicated the causative agent was more closely related to Aino virus than to SBV itself [28]. This finding underscores the complexity of serological surveillance in regions where multiple, antigenically related orthobunyaviruses co-circulate [28].

Further east, serological surveys have provided evidence of SBV exposure in Iran. A study in eastern Iran detected SBV antibodies in 12.45% of cattle, identifying breed, age, and geographic area as significant risk factors [38]. Another study in western Iran reported a 14.68% seroprevalence in horses, suggesting a broader host range than initially appreciated and indicating active circulation in the region [41]. In Iraq, a high seroprevalence of 74.07% in cows and 63.15% in buffaloes was reported, with the highest rates observed in younger animals and during the spring season, pointing to widespread and recent virus activity [34]. These findings from the Middle East and Asia suggest that SBV is not confined to Europe and that its distribution is likely more extensive than currently documented, potentially limited by a lack of surveillance in many countries [15, 33].

In Africa, the evidence for SBV circulation is more limited but nonetheless significant. A study in Namibia detected antibodies against SBV in cows that had delivered stillborn and malformed calves, alongside seropositivity for bluetongue virus and epizootic hemorrhagic disease virus, suggesting that SBV may be circulating in southern Africa [57]. However, the lack of virus neutralization confirmation in some of these early studies and the potential for cross-reactivity with other endemic Simbu serogroup viruses, such as Shamonda or Sathuperi, necessitates caution in interpretation [28, 57]. The global distribution of SBV is likely influenced by the presence of competent Culicoides vectors, which are found on every continent except Antarctica. The potential for SBV to be introduced into new regions, such as the Americas, is a constant concern, particularly given the presence of competent vectors like Culicoides sonorensis and the large, naïve ruminant populations in these areas [1, 42]. A comprehensive study in Brazil, which has a climate and vector population conducive to SBV transmission, failed to detect any evidence of the virus in over 2,500 samples, suggesting that despite favorable conditions, the virus has not yet been introduced or established in South America [42].

The Role of Wildlife in SBV Epidemiology

Wild ruminants play a significant role in the epidemiology of SBV, acting as sentinels, potential reservoirs, and indicators of virus circulation. Numerous serosurveys across Europe have demonstrated widespread exposure in a variety of wild species, including red deer, roe deer, fallow deer, mouflon, and wild boar [16, 22, 23, 33]. A comprehensive meta-analysis estimated the overall pooled seroprevalence in wild ruminants at 26%, with the highest rates observed in roe deer (46%) and fallow deer (30%) [33]. In Spain, a long-term study (2006–2015) detected SBV antibodies in 14.6% of wild artiodactyls, with seropositivity appearing only after 2011 and continuing through 2015, indicating endemic circulation [23]. Similarly, in France, SBV spread rapidly through wildlife populations, infecting species up to high altitudes (1500 meters) and demonstrating a much broader ecological reach than bluetongue virus [22].

The role of wildlife as a true reservoir, a population that can maintain the virus independently of domestic livestock, is a subject of ongoing investigation. In Belgium, a six-year study in wild cervids revealed a pattern of seroprevalence that mirrored the cyclical circulation seen in domestic animals, with peaks in 2012 and 2016 followed by rapid declines [43]. The authors concluded that wild cervids likely play no central role in the long-term maintenance of SBV and that the virus dynamics in wildlife are driven by spillover from livestock [43]. However, other studies suggest that wildlife could serve as a source for re-introduction of the virus into domestic herds once immunity wanes [46, 53]. In Slovenia, SBV antibodies were detected in 18.1% of wild ruminants, including young animals, demonstrating recent exposure and suggesting that these populations could be a potential source for re-emergence [46]. In the United Kingdom, a seroprevalence of 13.8% was found in wild deer, with higher rates in southern regions, supporting the idea that SBV is now endemic in British wildlife [53]. The detection of SBV RNA in spleen samples from wild ruminants in Spain further confirms active infection in these populations [23]. Zoo animals have also been proposed as valuable sentinels for monitoring SBV activity, with a study in Spain detecting seroconversion in a mouflon and an Asian elephant, indicating virus circulation in the surrounding environment [50]. The consensus from the literature is that while wild ruminants are frequently infected and can serve as excellent indicators of virus circulation, they are unlikely to be a primary reservoir capable of sustaining the virus independently over long periods without periodic re-introduction from livestock or continuous vector-borne transmission [22, 43].

Vector Ecology and Transmission Dynamics

The epidemiology of SBV is inextricably linked to the ecology of its Culicoides vectors. The virus is transmitted primarily by midges of the subgenus Avaritia, particularly the Culicoides obsoletus complex (including C. obsoletus, C. scoticus, C. dewulfi, and C. chiopterus), which are abundant in livestock farms across Europe [2, 20, 48]. Other species, such as C. pulicaris, C. punctatus, and C. imicola, have also been found to be competent vectors, with C. imicola showing exceptionally high infection rates in experimental settings [19, 20]. The vector competence of different Culicoides species and populations can vary significantly, influencing local transmission dynamics [19, 48].

The transmission season is highly seasonal, typically spanning from late spring to autumn, when adult midge activity is at its peak [2, 40]. The extrinsic incubation period (EIP), the time from a midge ingesting an infectious blood meal to becoming capable of transmitting the virus, is highly temperature-dependent. Microclimatic temperatures at the vector's resting sites are far more critical than standard meteorological data for estimating EIP. A study in Denmark demonstrated that the mean EIP for SBV during summer was 14 days when using microclimatic data, compared to 21 days using standard weather station data, highlighting the importance of fine-scale environmental modeling [52]. The ability of SBV to overwinter in temperate climates is a key factor in its endemicity. The virus can persist through cold months within the adult midge population, likely through a combination of prolonged survival of infected adults and vertical transmission (transovarial passage) to the next generation. Evidence for transovarial transmission was provided by the detection of SBV RNA in nulliparous (virgin) female and male Culicoides in Poland, which do not take a blood meal and thus could only have acquired the virus from an infected parent [44].

A fascinating aspect of SBV transmission biology is the existence of a "dead-end" host cycle. Virus variants isolated from malformed fetuses frequently harbor multiple mutations, including large deletions in the M segment encoding the Gc glycoprotein [6, 14]. These mutations, particularly the S111N substitution in the nucleoprotein, confer a significant fitness cost in the insect vector. Experimental infection of Culicoides sonorensis with a fetal-derived SBV variant (D281/12) resulted in no detectable replication, whereas the wild-type strain from a viremic cow replicated efficiently [7]. This demonstrates that while these mutant viruses can replicate in the unique environment of the mammalian fetus, they are unable to infect the midge vector and are thus excluded from the natural transmission cycle [6, 7, 14]. This phenomenon has profound implications for molecular epidemiology, as sequencing viruses from malformed fetuses would not reflect the circulating, transmissible virus population [14].

Risk Factors and Spatial Heterogeneity

The distribution of SBV is not uniform, even within endemic regions. A complex interplay of environmental, management, and host factors governs the risk of exposure. Multivariate analyses have consistently identified mean annual temperature as a primary driver of SBV seroprevalence. In southern Italy, a study found that higher mean annual temperatures were the main factor associated with increased seroprevalence in cattle and water buffalo, likely due to enhanced vector survival and viral replication rates [36]. Altitude also plays a significant role, with seroprevalence generally higher in lowlands compared to areas above 800 meters, although SBV has been shown to circulate at altitudes up to 1500 meters, a much higher range than bluetongue virus [22, 47]. Proximity to the coast has also been identified as a risk factor in some studies [36].

Management practices on farms are critical determinants of exposure. Extensive grazing systems, which bring livestock into closer and more prolonged contact with Culicoides habitats, are associated with a significantly higher risk of SBV infection compared to intensive, indoor housing [47]. Herd size is another important factor; larger herds present a larger target for vectors and are more likely to sustain virus circulation once introduced [39]. In Algeria, the implementation of rodent and pest control plans was identified as a protective factor, likely by reducing the overall insect burden on the farm [39]. The timing of breeding is a crucial management risk factor. Early lambing flocks that are bred in the summer, coinciding with peak midge activity, are at a much higher risk of infection during the critical early stages of gestation, leading to severe outbreaks of congenital malformations [37].

Host factors also contribute to epidemiological heterogeneity. Among domestic ruminants, cattle consistently show the highest seroprevalence, followed by sheep and then goats [33]. This may reflect differences in vector attraction, host behavior, or susceptibility. Age is a universal risk factor, with seroprevalence increasing with age due to cumulative exposure, while young animals are more likely to be seronegative and susceptible [26, 34]. The presence of multiple, antigenically related orthobunyaviruses in some regions can complicate serological interpretation. In Jordan, for example, antibodies detected by an SBV ELISA were later shown by cross-neutralization to be directed against Aino virus, a related Simbu serogroup virus [28]. This highlights the need for confirmatory testing, such as virus neutralization tests, to accurately determine SBV-specific seroprevalence in regions with complex orthobunyavirus ecology.

Diagnostics and Surveillance for Schmallenberg Virus

The establishment of robust diagnostic and surveillance frameworks for Schmallenberg virus (SBV) is paramount for understanding its epidemiology, mitigating its economic impact on ruminant production, and informing evidence-based control strategies. Since its emergence in 2011, a multifaceted approach encompassing molecular detection of viral RNA, serological identification of antibodies, and entomological monitoring of Culicoides vectors has been developed and refined. These tools are not merely academic; they are the operational backbone for national veterinary authorities, the World Organisation for Animal Health (WOAH), and the Food and Agriculture Organization (FAO) in managing this arboviral threat. The diagnostic landscape is characterized by a dynamic interplay between the need for high sensitivity during acute infection, the requirement for serological specificity to determine population exposure, and the unique challenges posed by the virus's biology, including its genetic stability in circulating strains versus high variability in fetal isolates [1, 6, 14].

Molecular Diagnostics: Detection of Viral RNA

Molecular detection of SBV RNA is the cornerstone of diagnosing acute infections, confirming viremia in adult animals, and identifying the virus in aborted fetuses, neonatal malformations, and vector pools. Real-time reverse transcription polymerase chain reaction (RT-PCR) assays, targeting various genomic segments, have been the primary tool since the virus's discovery [2, 20, 58].

Target Genes and Assay Design: The majority of validated RT-PCR assays target the small (S) segment, which encodes the nucleoprotein (N), due to its high copy number during replication, offering superior analytical sensitivity. However, the medium (M) segment, encoding the glycoproteins Gn and Gc, is also a target, particularly for phylogenetic analyses and for detecting variants that may escape S-segment-based detection due to mutations [67]. The development of both SYBR Green-based and probe-based (TaqMan) assays has provided flexibility for different laboratory settings. Probe-based assays generally offer higher specificity, while SYBR Green assays can be more cost-effective for initial screening. Azkur et al. (2020) developed and validated alternative RT-rtPCR assays targeting both the S and M segments, demonstrating high efficiency (99-103%) and detection limits as low as 10¹ copies/µL, which are critical for detecting low-level viremia or residual RNA in semen [63, 67].

Sample Matrices and Diagnostic Windows: The choice of sample matrix is dictated by the clinical phase of infection. During the acute viremic phase, which typically lasts 2-5 days in adult cattle and sheep, whole blood or serum is the sample of choice for RT-PCR [68]. For aborted fetuses or neonates with congenital malformations (arthrogryposis-hydranencephaly syndrome), the brain tissue is the most reliable sample, as the virus has a strong neurotropism in the developing fetus [62, 64, 65]. Other fetal tissues, such as spleen and placenta, can also be tested, but brain tissue consistently yields the highest viral loads. The detection of SBV RNA in the semen of bulls, albeit transient and at low levels, has necessitated the development of highly sensitive, accredited protocols for international trade, as required by some SBV-free importing countries [63]. These protocols, often ISO/IEC 17025 accredited, are designed to detect minute quantities of RNA to meet zero-risk trade policies, despite the fact that venereal transmission is not considered a significant route of spread [61, 63].

Genetic Stability and the Challenge of Fetal Variants: A critical nuance in molecular diagnostics is the stark contrast in genetic stability between circulating SBV strains and those found in malformed fetuses. The M-segment sequences of viruses detected in the blood of viremic adult animals across Europe over many years are remarkably stable, with nucleotide similarities of 99.4% to 100% [12, 14]. This stability means that standard RT-PCR assays remain effective for detecting circulating field virus. However, within the immunologically privileged environment of the developing fetus, the virus undergoes accelerated mutation, particularly within a "hot-spot" region of the M segment encoding the N-terminal domain of the Gc protein [6, 14]. These mutations, including point mutations, insertions, and large in-frame deletions of up to 612 nucleotides, can lead to immune evasion from neutralizing antibodies [14]. Critically, these fetal variants, such as the SBV_D281/12 isolate, possess a "dead-end" phenotype; they are highly attenuated or unable to replicate in Culicoides vectors, thus being excluded from the natural transmission cycle [6, 7]. For diagnostic purposes, this means that while standard assays will detect these variants, the presence of large deletions could theoretically lead to false negatives if primer/probe binding sites are compromised. Therefore, assays targeting multiple genome segments or highly conserved regions are recommended for comprehensive fetal screening [67].

Serological Diagnostics: Detecting Past Exposure and Population Immunity

Serological assays are indispensable for determining the prevalence of SBV infection, monitoring the dynamics of herd immunity, and conducting surveillance in both domestic and wild ruminant populations. The two principal methods are the enzyme-linked immunosorbent assay (ELISA) and the virus neutralization test (VNT).

Enzyme-Linked Immunosorbent Assays (ELISAs): Commercial ELISAs, both indirect and competitive (blocking) formats, are the workhorses of large-scale serosurveillance due to their high throughput, relatively low cost, and ease of standardization [1, 33, 36]. These assays typically detect antibodies against the nucleoprotein (N) or the glycoprotein Gc. The multi-species nature of many commercial kits allows for testing across cattle, sheep, goats, and even wildlife species without the need for species-specific conjugates [38, 41]. A systematic review and meta-analysis by Dagnaw et al. (2024) reported a pooled global seroprevalence of 49% in domestic ruminants using various serological tests, with the highest prevalence in cattle (59%), followed by sheep (37%) and goats (18%) [33]. This highlights the extensive exposure of livestock populations. However, ELISAs can exhibit cross-reactivity with other members of the Simbu serogroup, such as Aino virus or Akabane virus, which is a significant consideration in regions like the Middle East or Asia where these viruses co-circulate [28]. Therefore, positive ELISA results, especially in novel or non-endemic areas, should be confirmed by the more specific VNT.

Virus Neutralization Test (VNT): The VNT is the gold standard serological test, offering the highest specificity by detecting functional, neutralizing antibodies, primarily directed against the viral glycoproteins (Gn and Gc) [33, 36, 59]. It is essential for confirming SBV-specific antibodies and for differentiating SBV from other Simbu serogroup viruses through cross-neutralization assays [28]. The VNT requires live virus, which poses significant biosafety and logistical challenges, particularly in non-endemic countries where access to high-containment facilities and the virus itself is limited. To address this, recombinant vesicular stomatitis virus (VSV) chimeras expressing SBV glycoproteins have been developed as a safer, surrogate VNT platform that can be used in BSL-2 facilities, eliminating the need for live SBV [59]. The meta-analysis by Dagnaw et al. (2024) found that the highest detection rate of anti-SBV antibodies (66%) was achieved by VNT, underscoring its superior sensitivity in detecting past infection [33].

DIVA Capability and Vaccine Differentiation: A critical advancement in serological diagnostics is the ability to Differentiate Infected from Vaccinated Animals (DIVA). Licensed inactivated whole-virus vaccines induce antibodies against the N protein and the glycoproteins, making it impossible to distinguish vaccinated animals from those naturally infected using standard N-protein-based ELISAs [1, 10, 17]. This has driven the development of subunit, live-vectored, and DNA-based marker vaccines that lack the N protein. Consequently, a companion DIVA ELISA, which detects antibodies against the N protein, can be used in conjunction with a glycoprotein-based vaccine. Animals that are seropositive for glycoproteins but negative for N-protein antibodies are considered vaccinated, while those positive for both are considered naturally infected [10, 21, 27]. This capability is crucial for maintaining disease-free status for trade and for monitoring the effectiveness of vaccination campaigns.

Surveillance Strategies: From Emergence to Endemicity

Surveillance for SBV must be adaptive, shifting objectives as the epidemiological situation evolves from an emerging epidemic to an endemic state with cyclical re-emergence [24].

Passive and Active Surveillance in Livestock: Passive surveillance relies on the reporting of clinical signs, abortions, stillbirths, and congenital malformations, by farmers and veterinarians. This was the primary method for detecting the initial 2011-2012 epidemic and remains critical for identifying re-emergence events, as seen in Denmark in 2020-2021, where malformed calves were the first indication of virus circulation [51, 62, 64]. However, passive surveillance is limited by under-reporting and the non-specific nature of clinical signs in adult animals. Active surveillance, through periodic serological testing of sentinel herds or youngstock (animals born after the last vector season), provides a more accurate picture of virus circulation and population immunity [26, 45, 66]. For example, long-term serosurveys in Germany and Poland have revealed a cyclical pattern of SBV circulation, with major waves occurring every 3-4 years, driven by the influx of seronegative replacement animals [12, 26, 45]. The seroprevalence in young cattle in a German herd dropped from 74.9% in 2011 to 7.45% in 2015 before rising again to 58% in 2016, clearly demonstrating this phenomenon [26]. In the UK, mixed-methods studies have shown that the impact of re-emergence on sheep flocks is severe, with high perceived impacts on animal welfare, financial performance, and farmer well-being, reinforcing the need for early warning systems [37, 49].

Wildlife Surveillance: Wild ruminants, including red deer, roe deer, fallow deer, and mouflon, are susceptible to SBV and can serve as sentinels for virus circulation, often preceding or mirroring outbreaks in livestock [16, 22, 23, 43, 46, 60]. A large-scale serosurvey in Germany in 2023 revealed a dramatic increase in SBV seroprevalence in wild ruminants from 4.92% in 2022 to 40.15% in 2023, with 31.82% of young animals seropositive, indicating massive virus circulation [35]. Similarly, studies in Spain and France have shown widespread exposure in wildlife, with seroprevalence rates reaching up to 45.6% in fallow deer [16] and demonstrating that SBV can spread to higher altitudes more effectively than bluetongue virus [22]. While wildlife may not act as a true long-term reservoir, their monitoring provides a cost-effective, unbiased indicator of viral activity, especially in remote or mountainous areas where livestock surveillance is sparse [43, 46].

Entomological Surveillance: Direct detection of SBV RNA in Culicoides midges is the most definitive proof of active virus circulation in the vector population. Large-scale trapping and testing programs, such as the one established in Germany in 2018, are essential for monitoring infection rates and identifying vector species [2, 20, 44, 58]. From 2019 to 2023, the German program tested over 19,500 midge pools, finding SBV RNA every year with minimum infection rates (MIR) varying from 3.75 in 2022 to 135.47 in 2023 [2]. The primary vectors are members of the Obsoletus complex (C. obsoletus, C. scoticus), C. dewulfi, and C. chiopterus (subgenus Avaritia), but SBV has also been detected in C. pulicaris and C. punctatus (subgenus Culicoides) [2, 20]. Notably, the detection of SBV RNA in nulliparous females and, for the first time, in male midges in Poland suggests the possibility of transovarial transmission, which could be a mechanism for viral overwintering [44]. Entomological surveillance can provide early warning of virus circulation weeks or months before clinical cases appear in livestock, as demonstrated in France where SBV-positive midges were detected in August 2011, five months before the first congenital malformations were reported [20].

Challenges and Future Directions in Diagnostics

Despite significant progress, several challenges remain. The high genetic variability of fetal isolates necessitates continuous monitoring of circulating strains to ensure that molecular diagnostic assays remain effective [14]. The development of pan-Simbu serogroup assays could be valuable for detecting novel or emerging orthobunyaviruses. For serology, the lack of a perfect gold standard for all species, particularly wildlife, and the potential for cross-reactivity require careful interpretation of results. The WOAH and FAO recommend a combination of molecular and serological testing for definitive diagnosis and surveillance. Furthermore, the integration of syndromic surveillance, monitoring non-specific clinical signs like fever and milk drop, with targeted molecular testing could improve early detection of future incursions [24]. Finally, the development of rapid, point-of-care diagnostic tests, such as lateral flow devices, would empower veterinarians in the field to make immediate decisions, particularly during outbreaks in remote areas. The cyclical nature of SBV, with its predictable re-emergence every 3-6 years, underscores the absolute necessity for sustained, integrated surveillance programs that combine molecular, serological, and entomological components to protect the global ruminant population [12, 17, 56].

Clinical Manifestations and Pathological Effects in Ruminants

Schmallenberg virus (SBV) induces a spectrum of clinical and pathological outcomes that are critically dependent upon the host species, age, immunological status, and, most importantly, the gestational stage at which infection occurs. The clinical manifestations can be broadly dichotomized into an acute, often subclinical or transient disease in adult animals and a severe, teratogenic syndrome in the developing fetus, which constitutes the most economically and pathologically significant aspect of SBV infection [1, 11, 29]. The pathological effects observed in ruminants are a direct consequence of the virus's tropism for actively dividing cells, particularly in the central nervous system (CNS) and skeletal muscle precursor cells of the fetus, and its capacity for immune evasion within the unique environment of the developing conceptus [6, 7, 14].

Overview of Clinical Disease in Adult Ruminants

In adult cattle, sheep, and goats, SBV infection typically results in a mild, transient illness that is frequently subclinical and may go entirely unnoticed, especially in extensive management systems [11, 25, 29]. The initial descriptions of SBV, which led to its discovery, emerged from an outbreak in dairy cattle near the town of Schmallenberg, Germany, in late 2011. Affected animals presented with a spectrum of nonspecific clinical signs, including acute pyrexia (fever), a sudden and marked drop in milk yield, anorexia, and diarrhea [1, 11, 24, 25]. This acute syndrome is typically short-lived, resolving within a few days, and is seldom associated with mortality in adult animals [11, 25]. Indeed, in many naturally and experimentally infected adult animals, infection occurs without any overt clinical signs, with viremia being the only detectable indication of infection (typically lasting 2–6 days) [68]. Experimental inoculation of sheep via subcutaneous or intradermal routes effectively reproduces this viremia without eliciting clinical illness, confirming that the acute phase in adults is often clinically silent [68].

Acute Clinical Signs in Adult Cattle

The classic triad of fever, diarrhea, and a precipitous drop in milk production in dairy cows remains the hallmark of the acute adult infection, though it is important to recognize that these signs are highly variable and not pathognomonic [1, 11, 25]. The reduction in milk yield can be substantial and has been a significant driver of economic concern, particularly during the initial epidemic [11, 24]. The fever is generally moderate and transient. Diarrhea, when present, is often watery and non-hemorrhagic. Other less frequently reported signs include anorexia, depression, and a slight increase in respiratory rate [11].

Clinical Signs in Adult Sheep and Goats

In small ruminants, the acute clinical phase is even less pronounced than in cattle. While experimental infections have successfully induced viremia and seroconversion, clinical signs such as fever or diarrhea are rarely observed under natural or experimental conditions [68]. Adult sheep and goats are therefore often considered asymptomatic carriers during the acute phase of infection, with the virus's impact being exclusively realized through reproductive consequences in pregnant animals [11, 29]. The lack of a clear clinical signature in adult small ruminants makes clinical diagnosis impossible and underscores the reliance on serological or molecular detection methods for surveillance.

Pathological Effects of In-Utero Infection: The Teratogenic Syndrome

The most devastating and clinically significant consequences of SBV infection occur when immunologically naïve pregnant ruminants are infected during a critical window of gestation. The virus demonstrates a potent ability to cross the placental barrier and infect the developing fetus, leading to a spectrum of severe congenital malformations, abortion, stillbirth, and the birth of non-viable or weak offspring [1, 18, 29]. This syndrome is collectively referred to as arthrogryposis-hydranencephaly (AH) syndrome, and it is the most prominent pathological manifestation of SBV [11, 18, 25]. The pathological effects observed are remarkably similar to those induced by the closely related Akabane virus, highlighting a shared pathogenic mechanism among Simbu serogroup orthobunyaviruses [18, 25].

Pathophysiology of Vertical Transmission and Fetal Infection

The precise mechanisms of transplacental transmission are still under active investigation, but the outcome is clear: SBV has a profound tropism for fetal tissues, particularly the developing central nervous system and skeletal muscle [6, 14, 18]. The gestational age at infection is the single most critical determinant of the pathological outcome. The greatest vulnerability is observed during the first and second trimesters, a period of active organogenesis and neurogenesis. During this time, the fetal immune system is immature and incapable of mounting an effective antiviral response, creating a permissive environment for unchecked viral replication [6, 14, 18]. This unique immunological context is thought to drive the intense genetic variability observed in virus isolates from malformed fetuses, which is discussed below.

Gross Pathological Findings: Arthrogryposis and Central Nervous System Malformations

The two most characteristic and consistently reported gross pathological findings are arthrogryposis and hydranencephaly [11, 18, 25]. These lesions are frequently observed concurrently, though one may be more prominent.

• Arthrogryposis: This is a condition of persistent, rigid flexion or extension of multiple joints, giving the limbs a fixed, contracted appearance. It results from viral-induced damage to the developing motor neurons in the spinal cord and/or from direct infection and atrophy of fetal skeletal muscle. The affected limbs are often thin and underdeveloped (muscular hypoplasia) and are fixed in abnormal positions, such as carpal flexion or tarsal extension. This condition often leads to severe dystocia during parturition [11, 29, 37, 49].
• Hydranencephaly: This is a profound malformation of the brain in which the cerebral hemispheres are largely or completely replaced by fluid-filled sacs, with the brainstem and cerebellum often being relatively spared but also potentially affected [11, 51, 64]. Microscopically, this is a consequence of extensive necrosis and lysis of the developing brain parenchyma, followed by the formation of large cavities. Other CNS lesions frequently observed include porencephaly (cystic cavities in the brain), microencephaly (abnormally small brain), hydrocephalus (accumulation of cerebrospinal fluid within the ventricles), and cerebellar hypoplasia or dysplasia [11, 18, 64, 65].
• Other Malformations: Beyond the classic AH syndrome, SBV has been associated with a wider array of teratogenic effects. These include torticollis (wry neck), scoliosis (lateral curvature of the spine), severe brachygnathia inferior (shortened lower jaw), and, rarely, musculoskeletal defects like syndactyly (fusion of digits) [11, 25, 64]. Affected fetuses often exhibit generalized growth retardation and are born with a lower-than-normal birth weight [62].

Microscopic Pathology and Immunopathogenesis

Histopathological examination of affected fetal tissues reveals characteristic lesions that provide insight into the pathogenesis. In the central nervous system, the hallmark finding is a non-suppurative encephalomyelitis, characterized by lymphocytic and histiocytic perivascular cuffing, gliosis (proliferation of glial cells), and areas of neuronal necrosis and loss [65]. In skeletal muscle, lesions of atrophy and the replacement of myofibers with fibro-adipose tissue are observed.

A fascinating and clinically critical aspect of the pathogenesis is the high genetic variability observed in SBV isolates from malformed fetuses, particularly within the M segment encoding the Gc glycoprotein, which is the major target of neutralizing antibodies [6, 14, 15]. This variability, including point mutations, insertions, and large in-frame deletions, is concentrated in a "hot-spot" region that co-localizes with a key immunogenic domain on Gc [14]. It is hypothesized that the immature fetal environment, devoid of a fully functional adaptive immune system, permits the relentless replication of the virus, which inadvertently leads to the selection of variants that have undergone "immune evasion" mutations. These mutations allow the virus to escape neutralization by maternal antibodies that have crossed the placenta [6, 7, 14]. Critically, these fetal-derived variants, such as the unique D281/12 strain, have been demonstrated to be "dead-end" variants. They exhibit a profound loss of fitness for the insect vector (Culicoides midges) and are incapable of entering the natural mammalian-insect transmission cycle [6, 7, 14, 15]. This explains why these highly mutated strains are never found circulating in viremic adult animals or in Culicoides vectors; they are evolutionary cul-de-sacs that arise only within the protected niche of the infected fetus [6, 7, 14].

Outcomes Beyond Malformations: Abortion, Stillbirth, and Premature Birth

In addition to delivering lambs and calves with full-blown AH syndrome, SBV infection during pregnancy can result in a spectrum of other reproductive losses. Abortion at various stages of gestation is a frequently reported outcome [1, 39, 64, 65]. The viral-induced damage to the placenta and fetal tissues can trigger premature expulsion of the fetus. Stillbirth, defined as the birth of a dead, full-term fetus, is another common consequence, even in the absence of overt malformations [25, 29, 37]. Furthermore, the birth of weak, non-viable lambs or calves that are unable to stand, suckle, or regulate their body temperature is frequently reported, leading to high neonatal mortality within the first few days of life [11, 29, 37]. The severity of the pathological effects is directly related to the timing of infection; infection in early gestation leads to the most severe malformations, while later infection may result in the birth of weak but anatomically normal offspring [11].

Sequelae and Clinical Course in Lambs and Calves

Lambs and calves born with severe arthrogryposis are typically born dead or die shortly after birth due to an inability to suckle and breathe effectively. Dystocia is a major complication, frequently necessitating veterinary intervention in the form of traction, fetotomy, or Cesarean section [29, 37, 49, 62]. The physical toll on the ewe or cow can be significant, leading to maternal exhaustion, injury, and even death in severe cases [37, 49]. For those born alive with less severe CNS involvement, neurological deficits may be observed, including ataxia, blindness, inability to stand, and uncoordinated movements [11]. The economic and welfare impacts on affected flocks and herds are severe. Studies from the UK have documented dramatically increased lamb mortality rates (with total lamb losses of up to 42.6% reported in some flocks), a sharp decline in lamb rearing percentages, and a substantial burden on farmers' emotional well-being and financial performance during outbreak years [37, 49]. The impact is often most severe in early-lambing flocks where breeding coincides with the peak of vector activity in the preceding summer and autumn [37].

Impact on Maternal Health and Dystocia

The delivery of malformed fetuses, particularly those with arthrogryposis, torticollis, or hydrocephalus, presents a major obstetrical challenge [29, 37, 49, 62]. The abnormal fetal posture and conformation can prevent normal parturition, leading to prolonged and difficult labor. This results in an increased incidence of uterine inertia, fetal maldisposition, and vaginal or cervical lacerations. Ewes and cows may suffer from secondary complications such as metritis, retained placenta, and prolapse of the uterus or vagina [37, 49]. The need for increased veterinary assistance and the loss of breeding stock add to the considerable economic burden imposed by the disease.

Subclinical Infections and the Role of Wild Ruminants

A critical consideration in the epizootiology of SBV is the role of wild ruminants. Extensive serological surveys across Europe have demonstrated widespread exposure in a variety of wild species, including red deer, roe deer, fallow deer, mouflon, and wild boar [16, 22, 23, 33, 35, 46, 53, 60]. The seroprevalence in these populations can be high, often mirroring that of domestic livestock. However, crucially, clinical disease or overt pathological effects have rarely, if ever, been documented in free-ranging wild ruminants [16, 22, 23, 46]. This observation suggests that while wild ruminants are susceptible to infection and seroconvert, they appear to be relatively resistant to the teratogenic effects that are so devastating in domestic sheep and cattle. This may be due to differences in gestational timing or in the host-virus interaction at the fetal-maternal interface. Despite the lack of clinical disease, wild ruminant populations can serve as sentinel species for the detection of viral circulation, particularly in areas where domestic livestock are absent or vaccinated [16, 22, 43, 60]. Their seroprevalence can provide an early warning of viral re-emergence or the expansion of the enzootic area, a function that has been effectively utilized in monitoring programs across Europe [16, 22, 35, 43]. The high seroprevalence observed in juvenile wild ruminants, particularly in years of intense virus circulation, confirms that these species are actively involved in the transmission cycle, even if they are not reservoirs of clinical disease [22, 23, 35].

Vaccines and Immune Control Strategies for Schmallenberg Virus

The development of effective vaccines and immune control strategies for Schmallenberg virus (SBV) is a critical pillar in the management of this teratogenic orthobunyavirus, which has established an enzootic status across Central Europe with recurrent, wave-like re-emergence cycles occurring every two to four years [12, 17, 26, 45]. Since its emergence in 2011, vaccination has been recognized as one of the most important tools for disease control, primarily because SBV is transmitted by Culicoides biting midges, rendering vector control alone insufficient to prevent infection in naïve ruminant populations [1, 17, 30]. The immunological challenges are multifaceted: the need to protect pregnant dams during a critical gestational window, the requirement for marker vaccines that differentiate infected from vaccinated animals (DIVA), and the necessity to induce robust, long-lasting immunity that can counteract the waning herd immunity that drives cyclic re-emergence [10, 17, 26]. This section provides a comprehensive analysis of the landscape of SBV vaccine development, from licensed inactivated formulations to next-generation DIVA-capable candidates, while also examining innate immune mechanisms, antiviral peptide strategies, and the complex interplay of immune evasion within the unique environment of the developing fetus.

Inactivated Whole-Virus Vaccines and Their Limitations

The initial response to the SBV epizootic of 2011–2013 saw the rapid development and conditional licensure of inactivated whole-virus vaccines in several European countries [1, 10, 17, 18]. These vaccines, based on chemically inactivated SBV propagated in cell culture, were demonstrated to be efficacious in protecting cattle and sheep against experimental challenge, preventing viremia and subsequent transplacental transmission [10, 17]. Commercially available formulations, such as Bovilis SBV (MSD Animal Health) and SBVvax (CZ Vaccines), were granted marketing authorizations under exceptional circumstances [17, 30]. However, despite their proven efficacy, the uptake of these inactivated vaccines has been consistently low across Europe, rarely exceeding 20% of eligible livestock in most countries [17, 29, 30, 49]. Several factors explain this limited adoption. The cyclical nature of SBV circulation, characterized by intense activity every few years followed by periods of relative silence, creates epidemiological uncertainty regarding the optimal timing of vaccination [12, 17, 30]. High seroprevalence rates in older animals following a major wave (often exceeding 70–90% in adult cattle) lead farmers to perceive vaccination as unnecessary for the standing herd, leaving only naïve replacement stock at risk [17, 26]. Furthermore, the cost and labor associated with annual booster vaccinations in large commercial herds, particularly when the disease is perceived as sporadic or unpredictable, have been significant barriers [17, 30, 49]. Perhaps the most fundamental limitation of inactivated whole-virus vaccines is their inability to differentiate infected from vaccinated animals (lack of DIVA capability) [1, 10, 17]. This is a substantial drawback for surveillance programs and international trade, as seropositive vaccinated animals cannot be distinguished from those naturally infected, complicating efforts to monitor virus circulation and maintain disease-free status [1, 10, 27]. Importantly, the first commercially available inactivated vaccines were eventually withdrawn from the market in several countries, including the United Kingdom, due to declining demand, leaving the ruminant population increasingly vulnerable to future outbreaks [17, 29].

Subunit and Protein-Based DIVA Vaccine Candidates

The DIVA limitation of inactivated vaccines has driven intensive research into next-generation platforms that incorporate only specific viral antigens, primarily the viral glycoproteins Gn and Gc, which are responsible for receptor binding and membrane fusion, respectively [1, 5, 10, 21]. The rationale is straightforward: vaccinated animals develop antibodies against the vaccine antigen (typically Gc), while naturally infected animals produce antibodies against the nucleoprotein (N) and other internal proteins in addition to glycoproteins. This allows serological discrimination using N-protein-specific diagnostic tests [10, 21, 27]. The N-terminal domain of glycoprotein Gc (the “Gc head” and “head-stalk” region, comprising approximately 234 amino acids) has been identified as the primary target for neutralizing antibodies and is therefore the cornerstone of subunit vaccine design [10, 21, 27]. Wernike et al. (2017) demonstrated that immunization of cattle with a multivalent antigen containing the Gc domains of both SBV and the related Akabane virus, expressed in a mammalian system, conferred complete protection against SBV challenge, while also enabling DIVA serology [21]. Subsequent work refined this approach, showing that the complete head-stalk domain is superior to the Gc head alone in inducing protective immunity [10]. Importantly, bacterially expressed Gc proteins, while economically attractive, failed to confer protection, likely due to improper folding and lack of post-translational modifications required for native antigenic structure [10, 21]. This underscores the critical importance of expression systems for conformational epitopes.

Parallel efforts have explored the viral nucleoprotein (N) as a vaccine antigen, given its high conservation across orthobunyaviruses of the Simbu serogroup and its ability to induce non-neutralizing, cell-mediated immune responses [8, 31, 32]. Boshra et al. (2020) demonstrated that bacterially expressed SBV-N, co-administered with a veterinary-grade saponin adjuvant, protected IFNAR-/- mice against virulent SBV challenge, significantly reducing viremia and clinical signs despite the absence of neutralizing antibodies [31]. Protection was associated with interferon-γ secretion from splenocytes, indicating a T-helper 1 (Th1) cell-mediated mechanism [31]. Similarly, Guerra et al. (2023) identified an N-terminal fragment of the N protein (C4, amino acids 1–58) that is highly conserved (~87.1% homology) across the Simbu serogroup and, when used as a subunit vaccine, reduced viremia in SBV-challenged IFNAR-/- mice [8]. This fragment can be easily produced in bacterial cells and is amenable to nanoparticle formulation, making it a promising candidate for a broadly protective, multivalent vaccine against not only SBV but also related pathogens such as Akabane virus and Oropouche virus [8]. It is noteworthy, however, that early attempts to use monomeric Gc subunit vaccines (e.g., baculovirus-expressed Gc or Gn/Gc combinations) in cattle were disappointing; in one study, such vaccines failed to prevent viremia or confer clinical protection upon challenge, despite eliciting detectable antibody responses [69]. This failure suggests that subunit vaccines must be carefully designed to present antigens in a multimeric, properly oriented conformation to mimic the native viral spike and induce robust neutralizing antibody titers [10, 21, 69].

Viral Vector and DNA Vaccine Approaches

To overcome the immunogenicity hurdles of soluble protein subunits, viral-vectored and DNA-based platforms have been developed that deliver the antigen-encoding genetic material directly into host cells, leading to endogenous expression, proper post-translational processing, and presentation to both the humoral and cellular arms of the immune system [1, 21, 27, 32]. Wernike et al. (2018) evaluated the N-terminal Gc domain delivered by recombinant equine herpesvirus type 1 (rEHV-1) and modified vaccinia virus Ankara (rMVA) in a vaccination-challenge trial in cattle [27]. The rMVA-based vaccine induced robust SBV-specific antibody responses and conferred complete protection against challenge in all vaccinated animals, while the rEHV-1 vector provided partial protection (two of four animals) [27]. Both vector vaccines enabled DIVA serology, as vaccinated animals lacked antibodies against the viral N-protein [27]. This study highlights the superior immunogenicity of poxvirus vectors like MVA for orthobunyavirus antigens.

DNA vaccination, involving the direct injection of plasmid DNA encoding the antigen of interest, offers advantages of stability, ease of production, and lack of anti-vector immunity [21, 32]. Boshra et al. (2017) evaluated DNA constructs encoding the SBV N protein (both ubiquitinated and non-ubiquitinated forms) and the putative ectodomain of Gc (amino acids 678–947) in the IFNAR-/- mouse model [32]. The non-ubiquitinated N protein and the Gc ectodomain both significantly reduced viremia and protected mice from clinical disease, with protection apparently mediated by CD8+ T cells rather than neutralizing antibodies [32]. This finding is significant because it identifies two distinct immunological targets, the internal N protein and the surface-exposed Gc, that can be exploited in combination for optimized vaccine design [32]. More recently, a recombinant vesicular stomatitis virus (VSV) chimera expressing SBV glycoproteins has been constructed as a safe surrogate for virus neutralization tests, a tool that could also be adapted for vaccine purposes [59].

Modified Live, Scaffold Particle, and Combined Approaches

In addition to subunit and vectored platforms, modified live vaccines (MLVs) and scaffold particle vaccines have been explored. Classical MLVs, while potentially highly immunogenic, raise safety concerns regarding reversion to virulence and the risk of transplacental infection in pregnant animals [10, 17]. Consequently, research has focused on rationally attenuated reverse-genetics-derived deletion mutants. Wernike et al. (2022) reviewed the development of scaffold particle vaccines that present multimeric arrays of the Gc antigen on self-assembling protein platforms [10]. These virus-like particles (VLPs) mimic the repetitive, dense antigen display of native virions, triggering potent B-cell responses without the need for replicating virus. In target species, such scaffold particle vaccines have shown promising immunogenicity, and their design can be modular, allowing the inclusion of antigens from multiple orthobunyaviruses [10]. The ability to combine the immunodominant Gc head-stalk domain with the conserved N-terminal fragment of the N protein on a single scaffold particle could theoretically provide both humoral (antibody-mediated) and cellular (T-cell-mediated) protection, a strategy that warrants further investigation in large animal models [8, 10, 32].

The Challenge of Immune Evasion in the Fetal Environment and Implications for Vaccine Design

A critical and unique aspect of SBV immunobiology is the phenomenon of immune escape observed in the developing fetus. Wernike et al. (2021) conducted a seminal study demonstrating that SBV variants isolated from malformed fetuses harbor a “hot-spot” of high genetic variability within the N-terminal region of the Gc protein, which co-localizes with the main immunogenic domain [14]. These mutations, including point mutations, insertions, and large in-frame deletions (up to 612 nucleotides), frequently abolish the reactivity of the Gc protein with neutralizing monoclonal antibodies and polyclonal antisera derived from field-infected animals [14]. One natural deletion variant (SBV_D281/12), isolated from a sheep fetus, could not be neutralized effectively by antibodies in vitro and was highly attenuated in sheep, failing to replicate efficiently [7, 14]. Moreover, Sick et al. (2024) identified that the S segment of this fetal variant (encoding the nucleoprotein) is responsible for a marked replication deficit in Culicoides vector cells, characterized by a single point mutation (S111N) in the nucleoprotein that renders the virus a “dead-end” variant unable to complete the vector-mammalian transmission cycle [6]. This suggests that the fetal environment imposes unique selective pressures that favor antigenic variation at the cost of vector fitness [6, 7, 14]. For vaccine design, this has profound implications: any vaccine must induce a sufficiently broad and robust neutralizing antibody response to cover the antigenic diversity that can arise within a single infected fetus. The observation that circulating field strains (from viremic adult blood) exhibit extremely high genome stability (99.4–100% nucleotide similarity across years and countries) [12, 14] reassures that the circulating virus population does not rapidly evolve under immune pressure from vaccination, but the potential for antigenic drift within the dead-end fetal compartment remains a concern for comprehensive protection.

Innate Immune Mechanisms: Mx Proteins, Autophagy, and Antiviral Peptides

Beyond adaptive vaccine-induced immunity, understanding innate antiviral mechanisms offers insights into potential therapeutic and prophylactic strategies. Mx proteins are interferon-inducible GTPases that constitute a key component of the cell-intrinsic antiviral response. Bayrou et al. (2023) demonstrated that Mx1 proteins from bovine, canine, equine, and porcine species exhibit strong, dose-dependent antiviral activity against SBV in vitro [9]. This suggests that the innate interferon system is a powerful barrier to SBV replication, and that vaccines or immunomodulators capable of inducing a strong type I/III interferon response could enhance resistance at the mucosal or systemic level [9].

At the cellular level, Longobardi et al. (2025) revealed that SBV infection of BHK-21 cells induces autophagy at 48 hours post-infection while simultaneously downregulating the PI3K/Akt and Wnt/β-catenin signaling pathways [3]. Intriguingly, treatment with late-stage autophagy inhibitors (bafilomycin and chloroquine) significantly reduced SBV titers and prevented virus-induced cellular changes, whereas early-stage inhibitors or inducers had no effect [3]. This indicates that SBV hijacks the late stages of the autophagic pathway for its replication, identifying a potential target for host-directed antiviral therapy. While chloroquine is not a viable veterinary therapeutic at scale, the principle of targeting host factors required for viral replication is validated.

The exploration of host defense peptides (HDPs) represents another intriguing avenue. Giugliano et al. (2025) reported that scorpion venom-derived peptides pantinin-1 and pantinin-2 exhibit potent virucidal activity against SBV, with IC50 values around 10 µM and favorable selectivity indices in various cell lines [4]. These peptides appear to directly inactivate virus particles. Similarly, Zannella et al. (2025) screened a library of overlapping peptides spanning the SBV Gn and Gc glycoproteins and identified five Gc-derived peptides, predominantly located near the C-terminal domain, that inhibited SBV infection by at least 50% at 100 µM concentration [5]. No Gn peptides were inhibitory, and none were cytotoxic [5]. These findings identify specific domains within Gc that are critical for virus entry and could be exploited as peptide-based antiviral therapeutics or as leads for structure-based drug design [5]. While these are early-stage in vitro studies, they highlight the potential for alternative antiviral modalities beyond traditional vaccines.

Vaccination Strategies in the Context of Cyclical Re-Emergence and Herd Immunity

The practical implementation of vaccination must be aligned with the epidemiological dynamics of SBV. Long-term serological monitoring in Germany has revealed that herd immunity declines primarily through the replacement of seropositive animals by naïve youngstock rather than through waning antibody titers in individual animals [26]. In a monitored German dairy herd, within-herd seroprevalence fell from approximately 75% in 2011 to 40% in 2015, before increasing again to ~49% in 2016–2017 due to renewed virus circulation [26]. Similar patterns of cyclical seroprevalence have been documented across Europe, with major re-emergence events in 2012, 2016, and 2023 [12, 35, 43, 51, 54, 64]. This predictable decline in population immunity provides a clear rationale for targeted vaccination of replacement females (heifers, ewe lambs) before their first breeding season, when they are most vulnerable to transplacental infection [17, 26]. Modeling studies and field observations indicate that vaccinating naïve females before reproductive age is the most cost-effective strategy to prevent congenital malformations [17]. However, the unpredictable timing and magnitude of re-emergence waves (e.g., extreme SBV circulation in Germany in 2023 with a seroprevalence of 40% in wild ruminants) complicate decision-making [35]. Farmers and veterinarians must weigh the cost of annual vaccination against the risk of a major outbreak, a calculation made more difficult by the lack of real-time early warning systems [17, 30]. The establishment of coordinated sentinel surveillance programs integrating serological monitoring of sentinel herds, entomological surveillance of Culicoides populations, and meteorological modeling could provide the data needed to trigger timely vaccination campaigns [1, 24, 30]. Such systems are recommended by the World Organisation for Animal Health (WOAH) for vector-borne diseases and have been successfully applied for bluetongue virus; their adaptation for SBV could substantially reduce disease impact [1, 11, 18, 24]. In non-endemic regions, the priority is border biosecurity, monitoring of international trade (particularly of live animals and semen), and ensuring diagnostic preparedness, including access to safe surrogate virus neutralization tests like the VSV chimera [1, 59, 63]. The potential introduction of SBV into naive regions such as Brazil or Australia, where suitable vectors and susceptible hosts exist, remains a constant threat, and pre-emptive vaccine stockpiling may be warranted [1, 42].

Conclusion of Analysis: The Path Forward for Immune Control

The field of SBV vaccinology has advanced remarkably since 2011, progressing from empirical inactivated vaccines through to rationally designed DIVA-capable platforms based on antigenically defined protein domains, viral vectors, and DNA delivery. The identification of the Gc head-stalk domain as the key neutralizing immunogen, coupled with the discovery of protective T-cell epitopes within the N protein, provides a molecular roadmap for next-generation vaccine design. The demonstration that scaffold particle and MVA-vectored vaccines can confer complete protection in cattle while enabling DIVA serology represents a significant milestone. However, the commercial failure of early inactivated vaccines and the persistent low uptake of vaccines among farmers highlight that technological efficacy alone is insufficient; vaccines must be integrated into cost-effective, user-friendly, and epidemologically informed control programs. The development of multivalent vaccines that protect against multiple Simbu serogroup viruses (SBV, Akabane virus) would enhance economic incentives for vaccination [8, 21]. Furthermore, the continued elucidation of innate immune mechanisms, from the Mx GTPase system to autophagy and antiviral peptides, offers complementary strategies that could be deployed in outbreak settings or in immunocompromised populations. Ultimately, the sustained control of SBV will require a portfolio approach: enhanced surveillance to predict re-emergence, deployment of next-generation DIVA vaccines that can be integrated with eradication or control programs, vector management to reduce transmission pressure, and international cooperation to prevent transboundary spread. Without such comprehensive immune control strategies, the cyclical recrudescence of SBV will continue to impose significant economic and welfare burdens on the European ruminant sector

Integrated Control and Biosecurity Measures Against Schmallenberg Virus

The multifaceted challenge posed by Schmallenberg virus (SBV) necessitates a paradigm shift from reactive, outbreak-driven interventions to proactive, integrated control frameworks that simultaneously address the pathogen, its arthropod vector, and the susceptible host population. As SBV has transitioned from an emergent epidemic pathogen to an enzootic agent with cyclical recrudescence across much of Europe, the limitations of single-modality strategies, be it vaccination alone or vector suppression, have become starkly apparent [1, 12, 45]. A truly effective control program must therefore operate as a syncretic system, weaving together entomological surveillance, strategic immunoprophylaxis, biosecure animal movement protocols, and regionally adapted early warning architectures. The World Organisation for Animal Health (WOAH) has long advocated for such integrated vector-borne disease management, and the SBV experience offers a compelling case study for how these principles must be tailored to the unique biology of Culicoides-transmitted orthobunyaviruses.

Epidemiological Foundation for Integrated Control Strategies

Any control strategy must be grounded in the recognition that SBV transmission is governed by a complex interplay of vector bionomics, host immunity dynamics, and environmental drivers. The virus circulates in an enzootic cycle between ruminant reservoirs and Culicoides midges, with wild cervids such as roe deer and red deer serving as significant amplifying hosts that can maintain viral circulation even when domestic livestock seroprevalence wanes [16, 22, 33, 43]. This sylvatic reservoir complicates eradication efforts and necessitates that surveillance systems encompass both domestic and wildlife populations. The wave-like re-emergence pattern observed across Europe, with major circulation events occurring every 2–4 years following peaks in naïve animal accumulation, directly informs the timing of intervention deployment [12, 43, 51, 64]. In Germany, for example, seroprevalence in sentinel cattle herds declined from 74.9% in 2011 to just 39.9% by 2015, only to rebound sharply to 49.5% in 2016, driven by the influx of seronegative replacement animals [26]. This phenomenon, replicated across Belgium, the Netherlands, and the United Kingdom, underscores that herd immunity is a transient commodity and that integrated control must anticipate these cyclical vulnerability windows [30, 54, 66].

Vector Surveillance and Targeted Management

The cornerstone of any integrated SBV control program is comprehensive, longitudinal entomological surveillance. Monitoring Culicoides populations provides not only early warning of viral circulation but also critical data on vector species composition, abundance, and infection rates that inform the timing and intensity of control measures. Long-term monitoring programs in Germany, which analyzed over 511,000 individual midges from 79 sites between 2019 and 2023, have demonstrated that SBV circulates enzootically with highly variable minimum infection rates (MIR), ranging from 3.75 per 1,000 individuals in 2022 to 135.47 in 2023 [2]. This interannual variation, driven by climatic conditions affecting vector breeding and survival, means that control measures must be dynamically adjusted rather than applied uniformly. The predominant vectors in Central Europe belong to the subgenus Avaritia, particularly Culicoides obsoletus, C. scoticus, C. dewulfi, and C. chiopterus, though species such as C. pulicaris and C. punctatus within the subgenus Culicoides also contribute to transmission [2, 20, 58]. Importantly, experimental feeding studies have confirmed that both C. obsoletus and C. scoticus are susceptible to SBV infection, with infection rates of approximately 7.3% in membrane-fed members of the Avaritia subgenus [48]. The detection of SBV RNA in parous and nulliparous females, and even in male midges, raises the possibility of transovarial transmission, which could facilitate viral overwintering and complicate control efforts [44].

Chemical and Ecological Vector Management

Vector control strategies must be tailored to the specific ecology of Culicoides midges, which breed in moist, organic-rich substrates such as manure heaps, silage residues, and damp soil around farm buildings. Chemical control through the application of approved insecticides, primarily synthetic pyrethroids and organophosphates, can reduce adult midge populations, but their efficacy is limited by the short lifespan of adulticidal treatments, the development of insecticide resistance, and the impracticality of achieving complete coverage of vast breeding habitats [1]. Furthermore, the non-target effects of broad-spectrum insecticides on beneficial insects and aquatic ecosystems necessitate judicious use. Ecological management offers a more sustainable complement. Modifying farm environments to eliminate or reduce breeding sites, such as properly managing manure storage, ensuring adequate drainage, and removing decaying vegetation, can significantly suppress vector populations at their source [1, 39]. Interestingly, studies in Algeria identified the presence of molds in animal feed as a protective factor against SBV exposure, potentially because certain fungal metabolites deter Culicoides breeding or survival [39]. This finding highlights the importance of farm-level biosecurity audits that assess not only animal health parameters but also environmental conditions conducive to vector proliferation.

Biological Control and Novel Antiviral Approaches

Emerging biological control strategies offer promise for integration into comprehensive vector management programs. The identification of host defense peptides (HDPs) from scorpion venom, specifically pantinin-1 and pantinin-2, with potent virucidal activity against SBV represents a novel avenue for direct antiviral intervention at the vector-host interface [4]. With IC₅₀ values of approximately 10 µM and favorable selectivity indices, these peptides could theoretically be deployed as prophylactic or therapeutic agents in livestock, though significant challenges remain regarding in vivo efficacy, delivery systems, and regulatory approval. Similarly, the screening of overlapping peptides spanning the SBV glycoproteins Gc and Gn has identified five Gc-derived peptides that inhibit viral entry by more than 50% at 100 µM, all located near the carboxy-terminal domain [5]. These peptides target the class II fusion machinery essential for viral penetration and could serve as lead compounds for antiviral drug development. Additionally, the observation that the host sulfation pathway, mediated by PAPST1 and heparan sulfate proteoglycans, is required for efficient SBV entry presents a potential host-directed therapeutic target [13]. While direct antiviral treatments for SBV are not commercially available, these findings lay the groundwork for future integrated strategies that combine vector suppression with pharmacological blockade of viral replication.

Host Protection through Strategic Vaccination

Vaccination remains the most direct and scientifically validated method for protecting susceptible ruminant populations from SBV-induced reproductive losses. However, the SBV vaccine landscape is characterized by a dichotomy between what is scientifically feasible and what is practically implemented. Inactivated whole-virus vaccines were rapidly developed following the 2011 emergence and received marketing authorization in several European countries [10, 17, 18]. These vaccines effectively prevent clinical disease and reduce viremia, thereby also reducing the pool of infected animals from which vectors can acquire virus. Yet, their uptake has been consistently poor, often below 20% of eligible animals in surveyed UK flocks, owing to factors including cost, logistical challenges of administering two initial doses followed by annual boosters, and uncertainty about the risk of future outbreaks [30, 37, 49]. This low vaccination coverage perpetuates the cycle of herd immunity decline and recrudescent circulation.

DIVA Vaccine Development and Marker Vaccination

A critical limitation of conventional inactivated vaccines is their inability to differentiate infected from vaccinated animals (DIVA), which complicates serosurveillance and international trade certification [1, 10]. The development of DIVA-capable vaccines has therefore been a major research priority. Several promising candidates have been evaluated, including subunit vaccines based on the N-terminal domain of the Gc glycoprotein, live-vectored vaccines delivered by modified vaccinia virus Ankara (MVA) or equine herpesvirus type 1 (EHV-1), and DNA vaccines encoding the nucleoprotein or glycoprotein fragments [8, 10, 21, 27, 32]. These marker vaccines induce protective immunity while serologically differentiating vaccinated animals from those naturally infected, as vaccinated animals lack antibodies against the viral N-protein [21, 27]. In cattle, MVA-vectored Gc vaccines conferred complete protection against SBV challenge, with all vaccinated animals remaining SBV-negative by RT-PCR and serology for the N-protein [27]. Similarly, immunization with bacterially expressed SBV nucleoprotein adjuvanted with veterinary-grade saponin protected IFNAR-/- mice from lethal challenge and significantly reduced viremia, though protection was cell-mediated rather than neutralizing [31]. The identification of the C4 fragment of the nucleoprotein, a highly conserved 58-amino-acid region with 87.1% homology across Simbu serogroup orthobunyaviruses, offers the potential for a pan-Simbu vaccine that could protect against SBV, Akabane virus, and Oropouche virus simultaneously [8].

Vaccination Strategies and Economic Considerations

The implementation of vaccination programs must be strategically timed to precede vector activity seasons and target the most vulnerable demographic: nulliparous females entering their first gestation. Given that SBV causes fetal malformation only when naïve dams are infected during a critical window of gestation (typically days 75–120 in cattle and days 30–60 in sheep), vaccinating replacement heifers and ewe lambs before their first breeding season is the most cost-effective approach [10, 17, 18, 62]. This strategy minimizes fetal exposure without necessitating annual booster vaccination of the entire herd, though periodic re-vaccination may be required as immunity wanes over several years [26]. Economic analyses suggest that the cost of vaccination, approximately £1 per dose in the UK, is readily justified when weighed against the potential losses from an outbreak, which can include neonatal mortality rates exceeding 40%, severe dystocia requiring veterinary intervention, and substantial reductions in lambing percentages [37, 49]. Farmers who experienced SBV outbreaks reported median severity scores of 3.5–4.0 out of 5 for impacts on animal welfare, financial performance, and emotional well-being [37]. The decision to vaccinate is therefore not merely a clinical consideration but a risk management imperative.

Border Biosecurity and Movement Controls

For regions currently free of SBV, such as parts of Scandinavia, North America, and Australasia, the primary line of defense is robust border biosecurity that prevents the introduction of infected animals, contaminated genetic material, or windborne infected vectors [1, 42, 57, 70]. The virus is known to be shed transiently and at low levels in the semen of a small proportion of infected bulls, prompting the European Union and many importing countries to impose testing requirements for bovine semen batches [30, 63]. An ISO/IEC 17025 accredited real-time RT-PCR protocol has been established for sensitive detection of SBV RNA in semen, with a detection limit sufficient to identify the minute quantities typically shed [63]. While SBV RNA has not been detected in ram semen in the UK, the possibility of rare shedding cannot be entirely excluded, and continued surveillance of small ruminant genetic material is warranted [61]. Live animal importation from SBV-endemic areas should be accompanied by pre-export and post-arrival quarantine with serological and molecular testing, as viremic animals can introduce virus into naïve vector populations [1, 71, 72].

Windborne Vector Incursion Modeling

Perhaps the most challenging biosecurity threat is the long-distance windborne dispersal of infected Culicoides midges. Atmospheric dispersion modeling played a crucial role in understanding the introduction of SBV into Ireland in 2012, where retrospective analysis identified a single plausible window on August 10–11, 2012, during which meteorological conditions allowed transportation of infected midges from southern England to the Irish coast [55]. This finding highlights the utility of integrating meteorological modeling with entomological surveillance for early warning systems. In non-endemic regions, the establishment of sentinel traps at high-risk entry points, particularly along prevailing wind trajectories from endemic areas, coupled with real-time RT-PCR testing of trapped midges, can provide weeks to months of advance warning before clinical cases appear in livestock [1, 2, 24, 58]. The European Food Safety Authority (EFSA) and WOAH have endorsed such risk-based surveillance frameworks, which are far more efficient than random sampling [24].

Early Warning Systems and Sentinel Surveillance

The success of integrated control hinges on the ability to detect viral circulation before it results in widespread fetal losses. Because SBV infection in adult animals is typically subclinical or produces only transient, non-specific signs such as mild fever and decreased milk yield, passive surveillance based on clinical case reporting is insufficient [11, 24, 29]. Proactive sentinel surveillance programs that monitor seroconversion in naive youngstock or detect SBV RNA in vector populations are far more effective. In the Netherlands, a structured surveillance program was implemented in the post-epidemic phase, with periodic sampling of dairy herds to detect seroconversion in unvaccinated replacement heifers [24, 66]. This approach revealed that the maximum prevalence of herds with active SBV circulation was less than 1% in 2013, providing assurance of low-level endemicity rather than epidemic resurgence [66]. In Belgium, targeted serosurveillance in sheep flocks detected a dramatic increase in seroprevalence from 25% to 62% between June and September 2016, accurately predicting an impending wave of arthrogryposis-hydranencephaly cases in lambs born the following spring [51].

Wildlife can serve as effective sentinels for SBV circulation, often preceding detection in livestock by months or even years. In Spain, SBV antibodies were detected in wild ruminants, particularly fallow deer and red deer, during the 2011–2012 hunting season, at least five months before the first officially reported cases in livestock [16, 23]. Zoo animals, including Asian elephants and mouflon, have also demonstrated seroconversion events that correlate with regional circulation patterns [50]. The incorporation of wildlife sampling into national surveillance frameworks, as advocated by FAO and WOAH, provides a cost-effective means of monitoring viral activity over large geographic areas where livestock density is low.

Diagnostic Capacity and Molecular Surveillance

Robust diagnostic capacity underpins all surveillance and control activities. Real-time RT-PCR assays targeting the S and M genome segments have been developed and validated, with detection limits as low as 10¹ copies per microliter [67]. These assays are essential for detecting acute infections in viremic animals and for screening vector pools. However, the high genetic variability of the M segment, particularly in the N-terminal region of Gc, poses a challenge for primer and probe design, as mutations in this hypervariable region can lead to false-negative results [6, 14]. To mitigate this risk, assays should target conserved regions of the S segment or incorporate degenerate primers that accommodate sequence diversity [67]. Serological screening using commercial ELISAs, which detect antibodies against the N-protein, remains the mainstay of seroprevalence surveys, though virus neutralization tests are required for confirmatory testing and for distinguishing between SBV and related Simbu serogroup viruses [28, 33, 34, 36, 70]. The establishment of international reference laboratories and proficiency testing schemes, as coordinated by WOAH and the European Union Reference Laboratory for Bluetongue and SBV, ensures the harmonization of diagnostic methods across member states.

References

[1] Wang J, Jia Q, Xiang H, Wang F, Sun C, Chang J, et al.. Schmallenberg virus epidemiology and regional control strategies: diagnostics, vaccines, and vector management. Frontiers in Cellular and Infection Microbiology. 2025. DOI: https://doi.org/10.3389/fcimb.2025.1633030

[2] Zeiske S, Kampen H, Sick F, Dähn O, Voigt A, Heuser E, et al.. Monitoring of Schmallenberg virus, bluetongue virus and epizootic haemorrhagic disease virus in biting midges in Germany 2019–2023. Parasites & Vectors. 2025. DOI: https://doi.org/10.1186/s13071-025-06913-w

[3] Longobardi C, Lelli D, Corsa M, Pagnini U, Origgi F, Shin H, et al.. Evidence of autophagic and Wnt/β-catenin signaling occurrence during Schmallenberg virus (SBV) infection on BHK-21 cells.. Veterinary Microbiology. 2025. DOI: https://doi.org/10.1016/j.vetmic.2025.110609

[4] Giugliano R, Zannella C, Marca RD, Chianese A, Clemente LD, Monti A, et al.. Expanding the Antiviral Spectrum of Scorpion-Derived Peptides Against Toscana Virus and Schmallenberg Virus. Pathogens. 2025. DOI: https://doi.org/10.3390/pathogens14070713

[5] Zannella C, Grazioso R, Chianese A, Iovane V, Santella B, Montagnaro S, et al.. Screening and Identification of Multiple Peptides Homologous to the Fusion Glycoprotein Gc of Schmallenberg Virus Able to Inhibit Viral Infection. Transboundary and Emerging Diseases. 2025. DOI: https://doi.org/10.1155/tbed/1600862

[6] Sick F, Zeiske S, Beer M, Wernike K. Characterization of a natural 'dead-end' variant of Schmallenberg virus.. Journal of General Virology. 2024. DOI: https://doi.org/10.1099/jgv.0.002005

[7] Wernike K, Vasić A, Amler S, Sick F, Răileanu C, Dähn O, et al.. Schmallenberg virus non-structural proteins NSs and NSm are not essential for experimental infection of Culicoides sonorensis biting midges. bioRxiv. 2024. DOI: https://doi.org/10.1128/jvi.00343-25

[8] Guerra GS, Barriales D, Lorenzo G, Moreno S, Anguita J, Brun A, et al.. Immunization with a small fragment of the Schmallenberg virus nucleoprotein highly conserved across the Orthobunyaviruses of the Simbu serogroup reduces viremia in SBV challenged IFNAR-/- mice.. Vaccine. 2023. DOI: https://doi.org/10.1016/j.vaccine.2023.04.027

[9] Bayrou C, Laere AV, Van PD, Moula N, Garigliany M, Desmecht D. Anti-Schmallenberg Virus Activities of Type I/III Interferons-Induced Mx1 GTPases from Different Mammalian Species. Viruses. 2023. DOI: https://doi.org/10.3390/v15051055

[10] Wernike K, Aebischer A, Audonnet J, Beer M. Vaccine development against Schmallenberg virus: from classical inactivated to modified-live to scaffold particle vaccines. One Health Outlook. 2022. DOI: https://doi.org/10.1186/s42522-022-00069-8

[11] Collins Á, Doherty M, Barrett D, Mee J. Schmallenberg virus: a systematic international literature review (2011-2019) from an Irish perspective. Irish Veterinary Journal. 2019. DOI: https://doi.org/10.1186/s13620-019-0147-3

[12] Wernike K, Beer M. Re-circulation of Schmallenberg virus, Germany, 2019.. Transboundary and Emerging Diseases. 2020. DOI: https://doi.org/10.1111/tbed.13592

[13] Thamamongood T, Aebischer A, Wagner V, Chang M, Elling R, Benner C, et al.. A Genome-Wide CRISPR-Cas9 Screen Reveals the Requirement of Host Cell Sulfation for Schmallenberg Virus Infection. Journal of Virology. 2020. DOI: https://doi.org/10.1128/JVI.00752-20

[14] Wernike K, Reimann I, Banyard A, Kraatz F, Rocca SLL, Hoffmann B, et al.. High genetic variability of Schmallenberg virus M-segment leads to efficient immune escape from neutralizing antibodies. PLoS Pathogens. 2021. DOI: https://doi.org/10.1371/journal.ppat.1009247

[15] Behar A, Izhaki O, Rot A, Benor T, Yankilevich M, Leszkowicz-Mazuz M, et al.. Genomic Detection of Schmallenberg Virus, Israel. Emerging Infectious Diseases. 2021. DOI: https://doi.org/10.3201/eid2708.203705

[16] Jiménez‐Ruiz S, Risalde M, Acevedo P, Arnal M, Gómez-Guillamón F, Prieto P, et al.. Serosurveillance of Schmallenberg virus in wild ruminants in Spain.. Transboundary and Emerging Diseases. 2020. DOI: https://doi.org/10.1111/tbed.13680

[17] Wernike K, Beer M. Schmallenberg Virus: To Vaccinate, or Not to Vaccinate?. Vaccines. 2020. DOI: https://doi.org/10.3390/vaccines8020287

[18] Beer M, Wernike K. Akabane Virus and Schmallenberg Virus (Peribunyaviridae). Encyclopedia of Virology. 2019. DOI: https://doi.org/10.1016/B978-0-12-809633-8.20939-4

[19] Pagès N, Talavera S, Verdún M, Pujol N, Valle M, Bensaid A, et al.. Schmallenberg virus detection in Culicoides biting midges in Spain: First laboratory evidence for highly efficient infection of Culicoides of the Obsoletus complex and Culicoides imicola. Transboundary and Emerging Diseases. 2018. DOI: https://doi.org/10.1111/tbed.12653

[20] Ségard A, Gardès L, Jacquier E, Grillet C, Mathieu B, Rakotoarivony I, et al.. Schmallenberg virus in Culicoides Latreille (Diptera: Ceratopogonidae) populations in France during 2011‐2012 outbreak. Transboundary and Emerging Diseases. 2018. DOI: https://doi.org/10.1111/tbed.12686

[21] Wernike K, Aebischer A, Roman-Sosa G, Beer M. The N-terminal domain of Schmallenberg virus envelope protein Gc is highly immunogenic and can provide protection from infection. Scientific Reports. 2017. DOI: https://doi.org/10.1038/srep42500

[22] Rossi S, Viarouge C, Faure É, Gilot‐Fromont E, Gache K, Gibert P, et al.. Exposure of Wildlife to the Schmallenberg Virus in France (2011–2014): Higher, Faster, Stronger (than Bluetongue)!. Transboundary and Emerging Diseases. 2017. DOI: https://doi.org/10.1111/tbed.12371

[23] García‐Bocanegra I, Cano‐Terriza D, Vidal G, Rosell R, Paniagua J, Jiménez‐Ruiz S, et al.. Monitoring of Schmallenberg virus in Spanish wild artiodactyls, 2006–2015. PLoS ONE. 2017. DOI: https://doi.org/10.1371/journal.pone.0182212

[24] Veldhuis A, Mars J, Stegeman A, Schaik Gv. Changing surveillance objectives during the different phases of an emerging vector-borne disease outbreak: The Schmallenberg virus example.. Preventive Veterinary Medicine. 2019. DOI: https://doi.org/10.1016/J.PREVETMED.2019.03.008

[25] Pawaiya R, Gupta V. A review on Schmallenberg virus infection: a newly emerging disease of cattle, sheep and goats.. Veterinarni Medicina. 2018. DOI: https://doi.org/10.17221/7083-VETMED

[26] Wernike K, Holsteg M, Szillat KP, Beer M. Development of within-herd immunity and long-term persistence of antibodies against Schmallenberg virus in naturally infected cattle. BMC Veterinary Research. 2018. DOI: https://doi.org/10.1186/s12917-018-1702-y

[27] Wernike K, Mundt A, Link E, Aebischer A, Schlotthauer F, Sutter G, et al.. N-terminal domain of Schmallenberg virus envelope protein Gc delivered by recombinant equine herpesvirus type 1 and modified vaccinia virus Ankara: Immunogenicity and protective efficacy in cattle.. Vaccine. 2018. DOI: https://doi.org/10.1016/j.vaccine.2018.07.047

[28] Abutarbush S, Rocca AL, Wernike K, Beer M, Zuraikat KA, Sheyab OMA, et al.. Circulation of a Simbu Serogroup Virus, Causing Schmallenberg Virus‐Like Clinical Signs in Northern Jordan. Transboundary and Emerging Diseases. 2017. DOI: https://doi.org/10.1111/tbed.12468

[29] Jones O, Oultram J. Schmallenberg virus in the UK. Livestock. 2025. DOI: https://doi.org/10.12968/live.2024.0023

[30] Stavrou A, Daly J, Maddison B, Gough K, Tarlinton R. How is Europe positioned for a re-emergence of Schmallenberg virus?. The Veterinary Journal. 2017. DOI: https://doi.org/10.1016/j.tvjl.2017.04.009

[31] Boshra H, Lorenzo G, Charro D, Moreno S, Guerra GS, Sánchez I, et al.. A novel Schmallenberg virus subunit vaccine candidate protects IFNAR-/- mice against virulent SBV challenge. Scientific Reports. 2020. DOI: https://doi.org/10.1038/s41598-020-73424-2

[32] Boshra H, Charro D, Lorenzo G, Sánchez I, Lázaro B, Brun A, et al.. DNA vaccination regimes against Schmallenberg virus infection in IFNAR−/− mice suggest two targets for immunization. Antiviral Research. 2017. DOI: https://doi.org/10.1016/j.antiviral.2017.02.013

[33] Dagnaw M, Solomon A, Dagnew B. Serological prevalence of the Schmallenberg virus in domestic and wild hosts worldwide: a systematic review and meta-analysis. Frontiers in Veterinary Science. 2024. DOI: https://doi.org/10.3389/fvets.2024.1371495

[34] Taha FY, Moosa D, Alimam HM, Alhankawe OK. SEROLOGICAL INVESTIGATION OF SCHMALLENBERG VIRUS IN CATTLE IN MOSUL CITY, IRAQ. Assiut veterinary medical journal. 2025. DOI: https://doi.org/10.21608/avmj.2025.359705.1580

[35] Wernike K, Fischer L, Twietmeyer S, Beer M. Extensive Schmallenberg virus circulation in Germany, 2023. Veterinary Research. 2024. DOI: https://doi.org/10.1186/s13567-024-01389-5

[36] Ferrara G, Wernike K, Iovane G, Pagnini U, Montagnaro S. First evidence of schmallenberg virus infection in southern Italy. BMC Veterinary Research. 2023. DOI: https://doi.org/10.1186/s12917-023-03666-5

[37] Glover M, Blake N, Phythian C. Impacts of Schmallenberg virus infection in early lambing sheep flocks following the second wave of virus circulation in South West England in 2012/2013: a mixed-methods descriptive study. Veterinary Evidence. 2023. DOI: https://doi.org/10.18849/ve.v8i1.604

[38] Rasekh M, Sarani A, Jafari A. First detection of Schmallenberg virus antibody in cattle population of eastern Iran. Veterinary Research Forum. 2022. DOI: https://doi.org/10.30466/vrf.2021.135144.3032

[39] Djellata N, Yahimi A, Hanzen C, Saegerman C. Schmallenberg virus: seroprevalence, risk and protective factors in aborted dairy cows in Algeria. Veterinaria México OA. 2026. DOI: https://doi.org/10.22201/fmvz.24486760e.2026.1449

[40] Veljović L, Zoric JM, Glišić D, Nišavić J, Maletić J, Milićević V. Seroprevalence of Schmallenberg Virus in Sheep in Belgrade Epizootic Area. Acta Veterinaria. 2023. DOI: https://doi.org/10.2478/acve-2023-0038

[41] Mahdavi S, Salehzadeh M, Montazeri M. Detection of Schmallenberg virus antibody in equine population of Kurdistan province, west of Iran. Journal of the Hellenic Veterinary Medical Society. 2023. DOI: https://doi.org/10.12681/jhvms.29598

[42] Martins MdSN, Pituco EM, Taniwaki S, Okuda L, Richtzenhain L. Schmallenberg virus: research on viral circulation in Brazil. Brazilian Journal of Microbiology. 2021. DOI: https://doi.org/10.1007/s42770-021-00637-6

[43] Bayrou C, Lesenfants C, Paternostre J, Volpe R, Moula N, Coupeau D, et al.. Schmallenberg virus, cyclical reemergence in the core region: a seroepidemiologic study in wild cervids, Belgium, 2012-2017.. Transboundary and Emerging Diseases. 2021. DOI: https://doi.org/10.1111/tbed.14136

[44] Kęsik-Maliszewska J, Larska M, Collins Á, Rola J. Post-Epidemic Distribution of Schmallenberg Virus in Culicoides Arbovirus Vectors in Poland. Viruses. 2019. DOI: https://doi.org/10.3390/v11050447

[45] Kęsik-Maliszewska J, Collins Á, Rola J, Blanco-Penedo I, Larska M. Schmallenberg virus in Poland endemic or re-emerging? A six-year serosurvey.. Transboundary and Emerging Diseases. 2020. DOI: https://doi.org/10.1111/tbed.13870

[46] Vengušt G, Vengušt DŽ, Toplak I, Rihtarič D, Kuhar U. Post‐epidemic investigation of Schmallenberg virus in wild ruminants in Slovenia. Transboundary and Emerging Diseases. 2020. DOI: https://doi.org/10.1111/tbed.13495

[47] Jiménez-Martín D, Cano‐Terriza D, Díaz-Cao JM, Pujols J, Fernández-Morente M, García‐Bocanegra I. Epidemiological surveillance of Schmallenberg virus in small ruminants in southern Spain.. Transboundary and Emerging Diseases. 2020. DOI: https://doi.org/10.1111/tbed.13874

[48] Barber J, Harrup L, Silk RN, Veronesi E, Gubbins S, Bachanek-Bankowska K, et al.. Blood-feeding, susceptibility to infection with Schmallenberg virus and phylogenetics of Culicoides (Diptera: Ceratopogonidae) from the United Kingdom. Parasites & Vectors. 2018. DOI: https://doi.org/10.1186/s13071-018-2650-x

[49] Stokes J, Tarlinton R, Lovatt F, Baylis M, Carson A, Duncan J. Survey to determine the farm-level impact of Schmallenberg virus during the 2016–2017 United Kingdom lambing season. The Veterinary Record. 2018. DOI: https://doi.org/10.1136/vr.104866

[50] Caballero‐Gómez J, García‐Bocanegra I, Navarro N, Guerra R, Martínez-Nevado E, Soriano P, et al.. Zoo animals as sentinels for Schmallenberg virus monitoring in Spain.. Veterinary Microbiology. 2020. DOI: https://doi.org/10.1016/j.vetmic.2020.108927

[51] Sohier C, Deblauwe I, Loo TV, Hanon J, Cay A, Regge ND. Evidence of extensive renewed Schmallenberg virus circulation in Belgium during summer of 2016 – increase in arthrogryposis‐hydranencephaly cases expected. Transboundary and Emerging Diseases. 2017. DOI: https://doi.org/10.1111/tbed.12655

[52] Haider N, Cuellar AC, Kjær L, Sørensen JH, Bødker R. Microclimatic temperatures at Danish cattle farms, 2000–2016: quantifying the temporal and spatial variation in the transmission potential of Schmallenberg virus. Parasites & Vectors. 2018. DOI: https://doi.org/10.1186/s13071-018-2709-8

[53] Southwell RM, Sherlock K, Baylis M. Cross-sectional study of British wild deer for evidence of Schmallenberg virus infection. The Veterinary Record. 2020. DOI: https://doi.org/10.1136/vr.105869

[54] Collins Á, Collins Á, Barrett DJ, Doherty ML, McDonnell M, Mee JF. Significant re‐emergence and recirculation of Schmallenberg virus in previously exposed dairy herds in Ireland in 2016. Transboundary and Emerging Diseases. 2017. DOI: https://doi.org/10.1111/tbed.12685

[55] McGrath G, More S, O’Neill R. Hypothetical route of the introduction of Schmallenberg virus into Ireland using two complementary analyses. The Veterinary Record. 2017. DOI: https://doi.org/10.1136/vr.104302

[56] Larska M. Schmallenberg virus: a cyclical problem. The Veterinary Record. 2018. DOI: https://doi.org/10.1136/vr.k5109

[57] Molini U, Dondona AC, Hilbert R, Monaco F. Antibodies against Schmallenberg virus detected in cattle in the Otjozondjupa region, Namibia. Journal of the South African Veterinary Association. 2018. DOI: https://doi.org/10.4102/jsava.v89i0.1666

[58] Voigt A, Kampen H, Heuser E, Zeiske S, Hoffmann B, Höper D, et al.. Bluetongue Virus Serotype 3 and Schmallenberg Virus in Culicoides Biting Midges, Western Germany, 2023. Emerging Infectious Diseases. 2024. DOI: https://doi.org/10.3201/eid3007.240275

[59] Guo H, Jiang Z, Wang J, Wang F, Jia Q, Bu Z, et al.. Construction and Characterization of a Vesicular Stomatitis Virus Chimera Expressing Schmallenberg Virus Glycoproteins. Veterinary Sciences. 2025. DOI: https://doi.org/10.3390/vetsci12090809

[60] Wernike K, Fischer L, Holsteg M, Aebischer A, Petrov A, Marquart K, et al.. Serological screening in wild ruminants in Germany, 2021/2022: No evidence of SARS‐CoV‐2, bluetongue virus or pestivirus spread but high seroprevalences against Schmallenberg virus. bioRxiv. 2022. DOI: https://doi.org/10.1111/tbed.14600

[61] Curwen A, Jones S, Stayley C, Eden L, McKay H, Davies P, et al.. Failure to detect Schmallenberg virus RNA in ram semen in the UK (2016–2018). Veterinary Record Open. 2022. DOI: https://doi.org/10.1002/vro2.39

[62] Agerholm J, Wernike K. Occurrence of malformed calves in April - May 2021 indicates an unnoticed 2020 emergence of Schmallenberg virus in Denmark.. Transboundary and Emerging Diseases. 2021. DOI: https://doi.org/10.22541/au.163424110.09214326/v1

[63] Dastjerdi A, Rocca SLL, Karuna S, Finnegan C, Peake J, Steinbach F. Examining bull semen for residues of Schmallenberg virus RNA. Transboundary and Emerging Diseases. 2021. DOI: https://doi.org/10.1111/tbed.14275

[64] Delooz L, Saegerman C, Quinet C, Petitjean T, Regge ND, Cay B. Resurgence of Schmallenberg Virus in Belgium after 3 Years of Epidemiological Silence.. Transboundary and Emerging Diseases. 2017. DOI: https://doi.org/10.1111/tbed.12552

[65] Szeredi L, Dán Á, Malik P, Jánosi S, Hornyák Á. Low incidence of Schmallenberg virus infection in natural cases of abortion in domestic ruminants in Hungary.. Acta Veterinaria Hungarica. 2020. DOI: https://doi.org/10.1556/004.2020.00002

[66] Veldhuis A, Mars M, Roos C, Wuyckhuise Lv, Schaik Gv. Two Years After the Schmallenberg Virus Epidemic in the Netherlands: Does the Virus still Circulate?. Transboundary and Emerging Diseases. 2017. DOI: https://doi.org/10.1111/tbed.12349

[67] Azkur AK, Poel WVDvd, Aksoy E, Honing RWHd, Yildirim M, Yıldız K. Development and validation of SYBR Green- and probe-based reverse-transcription real-time PCR assays for detection of the S and M segments of Schmallenberg virus. Journal of Veterinary Diagnostic Investigation. 2020. DOI: https://doi.org/10.1177/1040638720947199

[68] Martinelle L, Poskin A, Pozzo FD, Mostin L, Campe Wv, Cay A, et al.. Three Different Routes of Inoculation for Experimental Infection with Schmallenberg Virus in Sheep. Transboundary and Emerging Diseases. 2017. DOI: https://doi.org/10.1111/tbed.12356

[69] Endalew AD, Faburay B, Trujillo J, Gaudreault N, Davis A, Shivanna V, et al.. Immunogenicity and efficacy of Schmallenberg virus envelope glycoprotein subunit vaccines. Journal of Veterinary Sciences. 2019. DOI: https://doi.org/10.4142/jvs.2019.20.e58

[70] Pinto GdOA, Ferreira M, Oliveira PR, Samico-Fernandes EFT, Melo R, Junior JWP, et al.. Investigation of Schmallenberg virus and update on the serological status of Toxoplasma gondii in goat herds in the semiarid region of Pernambuco state, Brazil.. Veterinary Parasitology: Regional Studies and Reports. 2025. DOI: https://doi.org/10.1016/j.vprsr.2025.101284

[71] Al-Baroodi S. Seroprevelance of schmallenberg virus infection as emerging disease in cattle in Iraq. Iraqi journal of Veterinary Sciences. 2021. DOI: https://doi.org/10.33899/IJVS.2020.127071.1454

[72] Taha FY, Alhankawe OK. Serodiagnosis of schmallenberg virus infection in sheep in Nineveh governorate, Iraq. Iraqi Journal of Veterinary Sciences. 2022. DOI: https://doi.org/10.33899/ijvs.2022.136029.2557